adalimumab-adbm (Cyltezo) vs certolizumab pegol

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Crohn's Disease

Shared mechanism: TNF-alpha · full Crohn's Disease pipeline

adalimumab-adbm (Cyltezo)

Marketed by Boehringer Ingelheim

Approved in Crohn's Diseasemonoclonal antibody
Reliable signal

NCT02871635 · Phase 3 · completed

This was a randomized, double-blind trial against the reference adalimumab product, with a validated Crohn's disease activity score as the primary endpoint. Clinical response at week 4 was similar in both groups (risk ratio 0.945, 90% CI 0.870 to 1.028), within the prespecified non-inferiority margin, and 147 people were randomized against a planned 130.

Hanauer et al. (Lancet Gastroenterol Hepatol, 2021; PMID 34388360) report different figures for this outcome, clinical response in 61 of 68 patients (90%) with BI 695501 and 68 of 72 (94%) with the reference product, because the registry figures are model-based least-squares means.

Reported efficacy

Percentage of Patients With a Clinical Response (CDAI Decrease of ≥70 Compared With Baseline) at Week 4: Clinical response (CDAI decrease of 70 points or more) at week 4, BI 695501 vs Humira (modified full analysis set): 61/68 (90%) vs 68/72 (94%); adjusted risk ratio 0.945 (90% CI 0.870 to 1.028), lower limit above the exploratory non-inferiority margin of 0.76 (Hanauer 2021, Lancet Gastroenterol Hepatol). (met)

Result source: NCT02871635

certolizumab pegol · Cimzia

Marketed by UCB

Approved in Crohn's DiseasePEGylated anti-TNF Fab' fragment
Weak signal

NCT00552344 · Phase 3 · completed

This open-label study gave long-term certolizumab pegol to patients with Crohn's disease from study C87085. Its primary objective was safety and its primary outcomes were adverse events, so there is no efficacy result to call met or missed. Over up to 272 weeks, 89.6% of patients had an adverse event and 37.1% a serious one. Source: CT.gov posted results. Its registered primary outcome on ClinicalTrials.gov is "Percentage of Subjects With at Least One Adverse Event (AE) During the Duration of the Study C87088 (up to 272 Weeks)" (with 1 other safety or dose-finding measure). Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.

Reported efficacy

Percentage of Subjects in Clinical Remission at Week 6: Clinical remission at Week 6: 31.6% (95% CI 25.4-37.8) certolizumab pegol vs 25.4% (95% CI 19.5-31.3) placebo; no p-value reported (missed)

Result source: NCT00552058

Results for Crohn's Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointadalimumab-adbm (Cyltezo)certolizumab pegol
Clinical remission (induction)—Not reported31.6% vs 25.4%+6.2 vs placebowk 6 · n 215NCT00552058
2 other results
  • 26.5% vs 19.1% wk 4 · n 215 · Phase 3 · secondary NCT00552058
  • 23.3% vs 15.8% wk 2 · n 215 · Phase 3 · secondary NCT00552058
Endoscopic response (induction)—Not reported—Not posted · NCT00152425
Clinical remission (maintenance)68.6% vs 76.2%vs Humira EUwk 24 · n 68NCT0287163537.5% vs 35%+2.5 vs placebowk 34 · n 16NCT00356408
1 other result
  • 3% vs 35% wk 34 · n 33 · Phase 3 · secondary NCT00356408
Endoscopic response (maintenance)—Not reported—Not posted · NCT00152425

Clinical remission (induction)

adalimumab-adbm (Cyltezo)
—Not reported
certolizumab pegol
31.6% vs 25.4%+6.2 vs placebowk 6 · n 215NCT00552058
2 other results
  • 26.5% vs 19.1% wk 4 · n 215 · Phase 3 · secondary NCT00552058
  • 23.3% vs 15.8% wk 2 · n 215 · Phase 3 · secondary NCT00552058

Endoscopic response (induction)

adalimumab-adbm (Cyltezo)
—Not reported
certolizumab pegol
—Not posted · NCT00152425

Clinical remission (maintenance)

adalimumab-adbm (Cyltezo)
68.6% vs 76.2%vs Humira EUwk 24 · n 68NCT02871635
certolizumab pegol
37.5% vs 35%+2.5 vs placebowk 34 · n 16NCT00356408
1 other result
  • 3% vs 35% wk 34 · n 33 · Phase 3 · secondary NCT00356408

Endoscopic response (maintenance)

adalimumab-adbm (Cyltezo)
—Not reported
certolizumab pegol
—Not posted · NCT00152425
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. adalimumab-adbm (Cyltezo): 4 of 4 rows · certolizumab pegol: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricadalimumab-adbm (Cyltezo)certolizumab pegol
Dropout rate
25%BI 695501
NCT02871635 · Phase 3 · Crohn's Disease · phase 3
show 2 more results
—BI 695501 (Baseline - Week 24 + 10
NCT02871635 · Phase 3 · Crohn's Disease · phase 3
—BI 695501 (Week 24 - Week 46 + 10
NCT02871635 · Phase 3 · Crohn's Disease · phase 3
78.4%a
NCT00552344 · Phase 3 · monotherapy
show 24 more results
80.3%
NCT00160524 · Phase 3 · monotherapy
—400 mg every 2 weeks
NCT00308581 · Phase 3 · monotherapy
—400 mg every 4 weeks
NCT00308581 · Phase 3 · monotherapy
69.5%400 mg
NCT00333788 · Phase 3 · monotherapy · Crohn's Disease · phase 3
92.3%
NCT00160706 · Phase 3 · monotherapy
—400 mg
NCT00356408 · Phase 3 · monotherapy
—CDP870/Completer
NCT00356408 · Phase 3 · monotherapy
—CDP870/Non-completer
NCT00356408 · Phase 3 · monotherapy
7.2%
NCT00552058 · Phase 3 · monotherapy
40.4%400 mg
NCT00297648 · Phase 3 · monotherapy · Crohn's Disease · phase 3
—Q2W
NCT03357471 · Phase 3 · registry result, not featured evidence · Crohn's Disease, Psoriatic Arthritis, Rheumatoid Arthritis · phase 3
—Q4W
NCT03357471 · Phase 3 · registry result, not featured evidence · Crohn's Disease, Psoriatic Arthritis, Rheumatoid Arthritis · phase 3
—High-dose (Weight Adjusted)
NCT01190410 · Phase 2 · registry result, not featured evidence
—Low-dose (Weight Adjusted)
NCT01190410 · Phase 2 · registry result, not featured evidence
—Re-Induction
NCT01190410 · Phase 2 · registry result, not featured evidence
46.2%400 mg / 200 mg
NCT00329420 · Phase 2 · registry result, not featured evidence
53.3%400 mg / 400 mg
NCT00329420 · Phase 2 · registry result, not featured evidence
26.7%CZP 400 mg / CZP 200 mg
NCT00329550 · Phase 2 · registry result, not featured evidence
25%CZP 400 mg / CZP 400 mg
NCT00329550 · Phase 2 · registry result, not featured evidence
3.1%400 mg
NCT00291668 · Phase 2 · registry result, not featured evidence
3.3%200 mg
NCT00291668 · Phase 2 · registry result, not featured evidence
0%400 mg Q2W
NCT04163016 · Phase 1 · registry result, not featured evidence
0%400 mg Q4W
NCT04163016 · Phase 1 · registry result, not featured evidence
0%200 mg Q2W
NCT04163016 · Phase 1 · registry result, not featured evidence
Discontinued due to AEs
5.6%BI 695501
NCT02871635 · Phase 3 · Crohn's Disease · phase 3
show 2 more results
—BI 695501 (Baseline - Week 24 + 10
NCT02871635 · Phase 3 · Crohn's Disease · phase 3
—BI 695501 (Week 24 - Week 46 + 10
NCT02871635 · Phase 3 · Crohn's Disease · phase 3
—a
NCT00552344 · Phase 3 · monotherapy
show 24 more results
35.8%
NCT00160524 · Phase 3 · monotherapy
—400 mg every 2 weeks
NCT00308581 · Phase 3 · monotherapy
—400 mg every 4 weeks
NCT00308581 · Phase 3 · monotherapy
18.9%400 mg
NCT00333788 · Phase 3 · monotherapy · Crohn's Disease · phase 3
51%
NCT00160706 · Phase 3 · monotherapy
—400 mg
NCT00356408 · Phase 3 · monotherapy
—CDP870/Completer
NCT00356408 · Phase 3 · monotherapy
—CDP870/Non-completer
NCT00356408 · Phase 3 · monotherapy
3.6%
NCT00552058 · Phase 3 · monotherapy
14.6%400 mg
NCT00297648 · Phase 3 · monotherapy · Crohn's Disease · phase 3
—Q2W
NCT03357471 · Phase 3 · registry result, not featured evidence · Crohn's Disease, Psoriatic Arthritis, Rheumatoid Arthritis · phase 3
—Q4W
NCT03357471 · Phase 3 · registry result, not featured evidence · Crohn's Disease, Psoriatic Arthritis, Rheumatoid Arthritis · phase 3
—High-dose (Weight Adjusted)
NCT01190410 · Phase 2 · registry result, not featured evidence
—Low-dose (Weight Adjusted)
NCT01190410 · Phase 2 · registry result, not featured evidence
—Re-Induction
NCT01190410 · Phase 2 · registry result, not featured evidence
—400 mg / 200 mg
NCT00329420 · Phase 2 · registry result, not featured evidence
—400 mg / 400 mg
NCT00329420 · Phase 2 · registry result, not featured evidence
26.7%CZP 400 mg / CZP 200 mg
NCT00329550 · Phase 2 · registry result, not featured evidence
12.5%CZP 400 mg / CZP 400 mg
NCT00329550 · Phase 2 · registry result, not featured evidence
—400 mg
NCT00291668 · Phase 2 · registry result, not featured evidence
—200 mg
NCT00291668 · Phase 2 · registry result, not featured evidence
0%400 mg Q2W
NCT04163016 · Phase 1 · registry result, not featured evidence
0%400 mg Q4W
NCT04163016 · Phase 1 · registry result, not featured evidence
0%200 mg Q2W
NCT04163016 · Phase 1 · registry result, not featured evidence
Serious AEs
—BI 695501
NCT02871635 · Phase 3 · Crohn's Disease · phase 3
show 2 more results
8.3%BI 695501 (Baseline - Week 24 + 10
NCT02871635 · Phase 3 · Crohn's Disease · phase 3
2.8%BI 695501 (Week 24 - Week 46 + 10
NCT02871635 · Phase 3 · Crohn's Disease · phase 3
37.1%a
NCT00552344 · Phase 3 · monotherapy
show 24 more results
40.3%
NCT00160524 · Phase 3 · monotherapy
13.4%400 mg every 2 weeks
NCT00308581 · Phase 3 · monotherapy
13.4%400 mg every 4 weeks
NCT00308581 · Phase 3 · monotherapy
31.9%400 mg
NCT00333788 · Phase 3 · monotherapy · Crohn's Disease · phase 3
44.5%
NCT00160706 · Phase 3 · monotherapy
14.6%400 mg
NCT00356408 · Phase 3 · monotherapy
0%CDP870/Completer
NCT00356408 · Phase 3 · monotherapy
12.1%CDP870/Non-completer
NCT00356408 · Phase 3 · monotherapy
5.4%
NCT00552058 · Phase 3 · monotherapy
38.2%400 mg
NCT00297648 · Phase 3 · monotherapy · Crohn's Disease · phase 3
0%Q2W
NCT03357471 · Phase 3 · registry result, not featured evidence · Crohn's Disease, Psoriatic Arthritis, Rheumatoid Arthritis · phase 3
0%Q4W
NCT03357471 · Phase 3 · registry result, not featured evidence · Crohn's Disease, Psoriatic Arthritis, Rheumatoid Arthritis · phase 3
40%High-dose (Weight Adjusted)
NCT01190410 · Phase 2 · registry result, not featured evidence
0%Low-dose (Weight Adjusted)
NCT01190410 · Phase 2 · registry result, not featured evidence
50%Re-Induction
NCT01190410 · Phase 2 · registry result, not featured evidence
23.1%400 mg / 200 mg
NCT00329420 · Phase 2 · registry result, not featured evidence
26.7%400 mg / 400 mg
NCT00329420 · Phase 2 · registry result, not featured evidence
33.3%CZP 400 mg / CZP 200 mg
NCT00329550 · Phase 2 · registry result, not featured evidence
31.3%CZP 400 mg / CZP 400 mg
NCT00329550 · Phase 2 · registry result, not featured evidence
9.4%400 mg
NCT00291668 · Phase 2 · registry result, not featured evidence
3.3%200 mg
NCT00291668 · Phase 2 · registry result, not featured evidence
—400 mg Q2W
NCT04163016 · Phase 1 · registry result, not featured evidence
20%400 mg Q4W
NCT04163016 · Phase 1 · registry result, not featured evidence
26.7%200 mg Q2W
NCT04163016 · Phase 1 · registry result, not featured evidence
Most frequent reported AEs
arthralgia 8.3%
respiratory tract infection 6.9%
crohn's disease 5.6%
NCT02871635 · Phase 3 · Crohn's Disease · phase 3
show 1 more result
nasopharyngitis 6.9%
weight increased 4.2%
arthralgia 2.8%
NCT02871635 · Phase 3 · Crohn's Disease · phase 3
a
crohn's disease 31.6%
abdominal pain 18.7%
upper respiratory tract infection 15.7%
NCT00552344 · Phase 3 · monotherapy
show 21 more results
crohn's disease 21.8%
nasopharyngitis 15.3%
abdominal pain 15%
NCT00160524 · Phase 3 · monotherapy
400 mg every 2 weeks
nasopharyngitis 17.2%
pyrexia 11.8%
arthralgia 10.8%
NCT00308581 · Phase 3 · monotherapy
400 mg every 4 weeks
headache 16.6%
nasopharyngitis 12.3%
nausea 11.2%
NCT00308581 · Phase 3 · monotherapy
400 mg
nasopharyngitis 27.5%
headache 20.5%
pyrexia 20.5%
NCT00333788 · Phase 3 · monotherapy · Crohn's Disease · phase 3
crohn's disease 34.5%
abdominal pain 20%
arthralgia 15.8%
NCT00160706 · Phase 3 · monotherapy
400 mg
crohn's disease 21.4% (placebo 7.1%)
arthralgia 18.4% (placebo 0%)
upper respiratory tract infection 13.6% (placebo 7.1%)
NCT00356408 · Phase 3 · monotherapy
arthralgia 25% (placebo 0%)
myalgia 18.8% (placebo 0%)
sinusitis 18.8% (placebo 7.1%)
NCT00356408 · Phase 3 · monotherapy
crohn's disease 33.3% (placebo 7.1%)
arthralgia 21.2% (placebo 0%)
nausea 18.2% (placebo 7.1%)
NCT00356408 · Phase 3 · monotherapy
headache 5.4% (placebo 4.7%)
abdominal pain 4.5% (placebo 3.7%)
arthralgia 4% (placebo 2.8%)
NCT00552058 · Phase 3 · monotherapy
400 mg
headache 33.7%
arthralgia 30.3%
nasopharyngitis 23.6%
NCT00297648 · Phase 3 · monotherapy · Crohn's Disease · phase 3
High-dose (Weight Adjusted)
abdominal pain upper 40%
nasopharyngitis 20%
nausea 20%
NCT01190410 · Phase 2 · registry result, not featured evidence
Low-dose (Weight Adjusted)
asthma exercise induced 25%
cough 25%
dizziness 25%
NCT01190410 · Phase 2 · registry result, not featured evidence
Re-Induction
abdominal injury 50%
anal fissure 50%
c-reactive protein increased 50%
NCT01190410 · Phase 2 · registry result, not featured evidence
400 mg / 200 mg
pyrexia 46.2% (placebo 11.1%)
nasopharyngitis 38.5% (placebo 55.6%)
contusion 15.4% (placebo 0%)
NCT00329420 · Phase 2 · registry result, not featured evidence
400 mg / 400 mg
nasopharyngitis 40% (placebo 55.6%)
pyrexia 20% (placebo 11.1%)
nausea 13.3% (placebo 5.6%)
NCT00329420 · Phase 2 · registry result, not featured evidence
nasopharyngitis 20% (placebo 22.2%)
nausea 13.3% (placebo 22.2%)
urinary tract infection 13.3% (placebo 0%)
NCT00329550 · Phase 2 · registry result, not featured evidence
nasopharyngitis 62.5% (placebo 22.2%)
dna antibody positive 12.5% (placebo 22.2%)
headache 12.5% (placebo 0%)
NCT00329550 · Phase 2 · registry result, not featured evidence
400 mg
nasopharyngitis 21.9% (placebo 31.3%)
nausea 6.3% (placebo 3.1%)
pharynx discomfort 6.3% (placebo 0%)
NCT00291668 · Phase 2 · registry result, not featured evidence
200 mg
nasopharyngitis 23.3% (placebo 31.3%)
nausea 6.7% (placebo 3.1%)
pharyngolaryngeal pain 6.7% (placebo 0%)
NCT00291668 · Phase 2 · registry result, not featured evidence
400 mg Q4W
influenza 40%
cystitis 20%
foetal vascular malperfusion 20%
NCT04163016 · Phase 1 · registry result, not featured evidence
200 mg Q2W
covid-19 40%
headache 20%
hypertension 13.3%
NCT04163016 · Phase 1 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for 21 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

adalimumab-adbm (Cyltezo)

CDAI ≥ 70 88% (n=68) vs 93.1% (n=72) Humira EU @ 4wk
responder rate · % of participants
NCT02871635 · Phase 3 · Crohn's Disease · phase 3
show 1 more result
87.4% (n=68) vs 87.4% (n=72) Humira EU @ 24wk
NCT02871635 · Phase 3 · Crohn's Disease · phase 3

certolizumab pegol

Clinical Remission 46.1% (n=89) @ 10wk400 mg
responder rate · % of participants
No placebo or comparator arm
NCT00297648 · Phase 3 · monotherapy · Crohn's Disease · phase 3
show 2 more results
27% (n=89) @ 54wk400 mg
NCT00297648 · Phase 3 · monotherapy · Crohn's Disease · phase 3
54.7% (n=592) @ 364wk
NCT00160524 · Phase 3 · monotherapy
HBI 21.7% (n=594) @ 364wk
responder rate · % of participants
No placebo or comparator arm
NCT00160524 · Phase 3 · monotherapy
show 2 more results
52.8% (n=307) @ 362wk
NCT00160706 · Phase 3 · monotherapy
65.6% (n=299) @ 362wk
NCT00160706 · Phase 3 · monotherapy
CDAI-100 37.4% (n=187) @ 26wk400 mg every 4 weeks
responder rate · % of participants
Maintenance
No placebo or comparator arm
Response
NCT00308581 · Phase 3 · monotherapy · converted to % from 70 participants as posted
show 1 more result
35.5% (n=186) @ 26wk*400 mg every 2 weeks
Response
NCT00308581 · Phase 3 · monotherapy · converted to % from 66 participants as posted
CDAI-70 40.1% (n=187) @ 26wk400 mg every 4 weeks
responder rate · % of participants
Maintenance
No placebo or comparator arm
Response
NCT00308581 · Phase 3 · monotherapy · converted to % from 75 participants as posted
show 1 more result
40.3% (n=186) @ 26wk*400 mg every 2 weeks
Response
NCT00308581 · Phase 3 · monotherapy · converted to % from 75 participants as posted
Clinical Remission 27.3% (n=187) @ 26wk400 mg every 4 weeks
responder rate · % of participants
Maintenance
No placebo or comparator arm
Remission
NCT00308581 · Phase 3 · monotherapy · converted to % from 51 participants as posted
show 1 more result
28% (n=186) @ 26wk*400 mg every 2 weeks
Remission
NCT00308581 · Phase 3 · monotherapy · converted to % from 52 participants as posted
CDAI 175.62 score @ 8wk400 mg every 4 weeks
absolute value · score
Maintenance
No placebo or comparator arm
NCT00308581 · Phase 3 · monotherapy
show 19 more results
169.18 score @ 8wk400 mg every 2 weeks
NCT00308581 · Phase 3 · monotherapy
164.65 score @ 10wk400 mg every 4 weeks
NCT00308581 · Phase 3 · monotherapy
162.86 score @ 10wk400 mg every 2 weeks
NCT00308581 · Phase 3 · monotherapy
173.83 score @ 12wk400 mg every 4 weeks
NCT00308581 · Phase 3 · monotherapy
163.78 score @ 12wk400 mg every 2 weeks
NCT00308581 · Phase 3 · monotherapy
162.34 score @ 14wk400 mg every 4 weeks
NCT00308581 · Phase 3 · monotherapy
158.68 score @ 14wk400 mg every 2 weeks
NCT00308581 · Phase 3 · monotherapy
163.73 score @ 16wk400 mg every 4 weeks
NCT00308581 · Phase 3 · monotherapy
156.05 score @ 16wk400 mg every 2 weeks
NCT00308581 · Phase 3 · monotherapy
153.38 score @ 18wk400 mg every 4 weeks
NCT00308581 · Phase 3 · monotherapy
156.64 score @ 18wk400 mg every 2 weeks
NCT00308581 · Phase 3 · monotherapy
162.79 score @ 20wk400 mg every 4 weeks
NCT00308581 · Phase 3 · monotherapy
138.6 score @ 20wk400 mg every 2 weeks
NCT00308581 · Phase 3 · monotherapy
128.13 score @ 22wk400 mg every 4 weeks
NCT00308581 · Phase 3 · monotherapy
141.89 score @ 22wk400 mg every 2 weeks
NCT00308581 · Phase 3 · monotherapy
135.49 score @ 24wk400 mg every 4 weeks
NCT00308581 · Phase 3 · monotherapy
139.5 score @ 24wk400 mg every 2 weeks
NCT00308581 · Phase 3 · monotherapy
122.37 score @ 26wk400 mg every 4 weeks
NCT00308581 · Phase 3 · monotherapy
131.41 score @ 26wk400 mg every 2 weeks
NCT00308581 · Phase 3 · monotherapy
CDAI -133.35 score @ 8wk400 mg every 4 weeks
absolute change · score
Maintenance
No placebo or comparator arm
NCT00308581 · Phase 3 · monotherapy
show 19 more results
-137.7 score @ 8wk400 mg every 2 weeks
NCT00308581 · Phase 3 · monotherapy
-145.16 score @ 10wk400 mg every 4 weeks
NCT00308581 · Phase 3 · monotherapy
-145.26 score @ 10wk400 mg every 2 weeks
NCT00308581 · Phase 3 · monotherapy
-134.51 score @ 12wk400 mg every 4 weeks
NCT00308581 · Phase 3 · monotherapy
-145.17 score @ 12wk400 mg every 2 weeks
NCT00308581 · Phase 3 · monotherapy
-145.54 score @ 14wk400 mg every 4 weeks
NCT00308581 · Phase 3 · monotherapy
-144.08 score @ 14wk400 mg every 2 weeks
NCT00308581 · Phase 3 · monotherapy
-141.9 score @ 16wk400 mg every 4 weeks
NCT00308581 · Phase 3 · monotherapy
-144.89 score @ 16wk400 mg every 2 weeks
NCT00308581 · Phase 3 · monotherapy
-150.38 score @ 18wk400 mg every 4 weeks
NCT00308581 · Phase 3 · monotherapy
-144.66 score @ 18wk400 mg every 2 weeks
NCT00308581 · Phase 3 · monotherapy
-139.98 score @ 20wk400 mg every 4 weeks
NCT00308581 · Phase 3 · monotherapy
-162.85 score @ 20wk400 mg every 2 weeks
NCT00308581 · Phase 3 · monotherapy
-171.52 score @ 22wk400 mg every 4 weeks
NCT00308581 · Phase 3 · monotherapy
-159.13 score @ 22wk400 mg every 2 weeks
NCT00308581 · Phase 3 · monotherapy
-165.06 score @ 24wk400 mg every 4 weeks
NCT00308581 · Phase 3 · monotherapy
-160.44 score @ 24wk400 mg every 2 weeks
NCT00308581 · Phase 3 · monotherapy
-176.85 score @ 26wk400 mg every 4 weeks
NCT00308581 · Phase 3 · monotherapy
-168.59 score @ 26wk400 mg every 2 weeks
NCT00308581 · Phase 3 · monotherapy
Duration of Response 4.21 months400 mg every 4 weeks
time to event · months
No placebo or comparator arm
NCT00308581 · Phase 3 · monotherapy · converted to months from 128 days as posted
show 1 more result
4.11 months*400 mg every 2 weeks
NCT00308581 · Phase 3 · monotherapy · converted to months from 125 days as posted
Steroid-free Remission 2.6% (n=76) @ 10wk400 mg every 4 weeks
responder rate · % of participants
Maintenance
No placebo or comparator arm
NCT00308581 · Phase 3 · monotherapy · converted to % from 2 participants as posted
show 17 more results
2.6% (n=78) @ 10wk*400 mg every 2 weeks
NCT00308581 · Phase 3 · monotherapy · converted to % from 2 participants as posted
3.9% (n=76) @ 12wk*400 mg every 4 weeks
NCT00308581 · Phase 3 · monotherapy · converted to % from 3 participants as posted
5.1% (n=78) @ 12wk*400 mg every 2 weeks
NCT00308581 · Phase 3 · monotherapy · converted to % from 4 participants as posted
3.9% (n=76) @ 14wk*400 mg every 4 weeks
NCT00308581 · Phase 3 · monotherapy · converted to % from 3 participants as posted
3.8% (n=78) @ 14wk*400 mg every 2 weeks
NCT00308581 · Phase 3 · monotherapy · converted to % from 3 participants as posted
6.6% (n=76) @ 16wk*400 mg every 4 weeks
NCT00308581 · Phase 3 · monotherapy · converted to % from 5 participants as posted
10.3% (n=78) @ 16wk*400 mg every 2 weeks
NCT00308581 · Phase 3 · monotherapy · converted to % from 8 participants as posted
9.2% (n=76) @ 18wk*400 mg every 4 weeks
NCT00308581 · Phase 3 · monotherapy · converted to % from 7 participants as posted
9% (n=78) @ 18wk*400 mg every 2 weeks
NCT00308581 · Phase 3 · monotherapy · converted to % from 7 participants as posted
10.5% (n=76) @ 20wk*400 mg every 4 weeks
NCT00308581 · Phase 3 · monotherapy · converted to % from 8 participants as posted
7.7% (n=78) @ 20wk*400 mg every 2 weeks
NCT00308581 · Phase 3 · monotherapy · converted to % from 6 participants as posted
10.5% (n=76) @ 22wk*400 mg every 4 weeks
NCT00308581 · Phase 3 · monotherapy · converted to % from 8 participants as posted
9% (n=78) @ 22wk*400 mg every 2 weeks
NCT00308581 · Phase 3 · monotherapy · converted to % from 7 participants as posted
11.8% (n=76) @ 24wk*400 mg every 4 weeks
NCT00308581 · Phase 3 · monotherapy · converted to % from 9 participants as posted
6.4% (n=78) @ 24wk*400 mg every 2 weeks
NCT00308581 · Phase 3 · monotherapy · converted to % from 5 participants as posted
10.5% (n=76) @ 26wk*400 mg every 4 weeks
NCT00308581 · Phase 3 · monotherapy · converted to % from 8 participants as posted
6.4% (n=78) @ 26wk*400 mg every 2 weeks
NCT00308581 · Phase 3 · monotherapy · converted to % from 5 participants as posted
Steroid Free 2.6% (n=76) @ 10wk400 mg every 4 weeks
responder rate · % of participants
Maintenance
No placebo or comparator arm
NCT00308581 · Phase 3 · monotherapy · converted to % from 2 participants as posted
show 17 more results
2.6% (n=78) @ 10wk*400 mg every 2 weeks
NCT00308581 · Phase 3 · monotherapy · converted to % from 2 participants as posted
5.3% (n=76) @ 12wk*400 mg every 4 weeks
NCT00308581 · Phase 3 · monotherapy · converted to % from 4 participants as posted
5.1% (n=78) @ 12wk*400 mg every 2 weeks
NCT00308581 · Phase 3 · monotherapy · converted to % from 4 participants as posted
6.6% (n=76) @ 14wk*400 mg every 4 weeks
NCT00308581 · Phase 3 · monotherapy · converted to % from 5 participants as posted
6.4% (n=78) @ 14wk*400 mg every 2 weeks
NCT00308581 · Phase 3 · monotherapy · converted to % from 5 participants as posted
10.5% (n=76) @ 16wk*400 mg every 4 weeks
NCT00308581 · Phase 3 · monotherapy · converted to % from 8 participants as posted
12.8% (n=78) @ 16wk*400 mg every 2 weeks
NCT00308581 · Phase 3 · monotherapy · converted to % from 10 participants as posted
11.8% (n=76) @ 18wk*400 mg every 4 weeks
NCT00308581 · Phase 3 · monotherapy · converted to % from 9 participants as posted
10.3% (n=78) @ 18wk*400 mg every 2 weeks
NCT00308581 · Phase 3 · monotherapy · converted to % from 8 participants as posted
11.8% (n=76) @ 20wk*400 mg every 4 weeks
NCT00308581 · Phase 3 · monotherapy · converted to % from 9 participants as posted
9% (n=78) @ 20wk*400 mg every 2 weeks
NCT00308581 · Phase 3 · monotherapy · converted to % from 7 participants as posted
11.8% (n=76) @ 22wk*400 mg every 4 weeks
NCT00308581 · Phase 3 · monotherapy · converted to % from 9 participants as posted
10.3% (n=78) @ 22wk*400 mg every 2 weeks
NCT00308581 · Phase 3 · monotherapy · converted to % from 8 participants as posted
14.5% (n=76) @ 24wk*400 mg every 4 weeks
NCT00308581 · Phase 3 · monotherapy · converted to % from 11 participants as posted
6.4% (n=78) @ 24wk*400 mg every 2 weeks
NCT00308581 · Phase 3 · monotherapy · converted to % from 5 participants as posted
13.2% (n=76) @ 26wk*400 mg every 4 weeks
NCT00308581 · Phase 3 · monotherapy · converted to % from 10 participants as posted
7.7% (n=78) @ 26wk*400 mg every 2 weeks
NCT00308581 · Phase 3 · monotherapy · converted to % from 6 participants as posted
Maintenance of 61.8% (n=166)400 mg
responder rate · % of participants
No placebo or comparator arm
NCT00333788 · Phase 3 · monotherapy · Crohn's Disease · phase 3
CDAI 53.3% (n=229)400 mg
responder rate · % of participants
No placebo or comparator arm
NCT00333788 · Phase 3 · monotherapy · Crohn's Disease · phase 3
show 2 more results
50.6% (n=89) @ 10wk400 mg
NCT00297648 · Phase 3 · monotherapy · Crohn's Disease · phase 3
32.6% (n=89) @ 54wk400 mg
NCT00297648 · Phase 3 · monotherapy · Crohn's Disease · phase 3

+ 27 further endpoints in the CSV export.

Psoriatic Arthritis

Shared mechanism: TNF-alpha · full Psoriatic Arthritis pipeline

adalimumab-adbm (Cyltezo)

Marketed by Boehringer Ingelheim

Approved in Psoriatic Arthritismonoclonal antibody
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

certolizumab pegol · Cimzia

Marketed by UCB

Approved in Psoriatic ArthritisPEGylated anti-TNF Fab' fragment
Weak signal

NCT03357471 · Phase 3 · completed

Allocation was NON_RANDOMIZED with masking NONE and no control/comparator arm (two parallel non-randomized dosing groups, not randomized treatment vs. control), so this defaults to 'weak' per the design test regardless of the very high reported success rates; the primary endpoint is also a device-usability surrogate rather than a hard clinical/endoscopic outcome.

No aligned efficacy figure on record for this race.

Results for Psoriatic Arthritis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointadalimumab-adbm (Cyltezo)certolizumab pegol
ACR20—Not reported51.9% vs 24.3%+27.6 vs placebo400 mg Q4W · wk 12 · n 135NCT01087788
3 other results
  • 58% vs 24.3% 200 mg Q2W · wk 12 · n 138 · Phase 3 · primary NCT01087788
  • 56.3% vs 23.5% 400 mg Q4W · wk 24 · n 135 · Phase 3 · secondary NCT01087788
  • 63.8% vs 23.5% 200 mg Q2W · wk 24 · n 138 · Phase 3 · secondary NCT01087788
ACR50—Not reported—Not reported
PASI 75—Not reported60.5% vs 15.1%+45.4 vs placebo400 mg Q4W · wk 24 · n 76NCT01087788
1 other result
  • 62.2% vs 15.1% 200 mg Q2W · wk 24 · n 90 · Phase 3 · secondary NCT01087788
Minimal disease activity—Not reported—Not reported
HAQ-DI, change—Not reported-0.5 vs -0.2−0.3 vs placebo400 mg Q4W · wk 24 · n 135NCT01087788
1 other result
  • -0.5 vs -0.2 200 mg Q2W · wk 24 · n 138 · Phase 3 · secondary NCT01087788

ACR20

adalimumab-adbm (Cyltezo)
—Not reported
certolizumab pegol
51.9% vs 24.3%+27.6 vs placebo400 mg Q4W · wk 12 · n 135NCT01087788
3 other results
  • 58% vs 24.3% 200 mg Q2W · wk 12 · n 138 · Phase 3 · primary NCT01087788
  • 56.3% vs 23.5% 400 mg Q4W · wk 24 · n 135 · Phase 3 · secondary NCT01087788
  • 63.8% vs 23.5% 200 mg Q2W · wk 24 · n 138 · Phase 3 · secondary NCT01087788

ACR50

adalimumab-adbm (Cyltezo)
—Not reported
certolizumab pegol
—Not reported

PASI 75

adalimumab-adbm (Cyltezo)
—Not reported
certolizumab pegol
60.5% vs 15.1%+45.4 vs placebo400 mg Q4W · wk 24 · n 76NCT01087788
1 other result
  • 62.2% vs 15.1% 200 mg Q2W · wk 24 · n 90 · Phase 3 · secondary NCT01087788

Minimal disease activity

adalimumab-adbm (Cyltezo)
—Not reported
certolizumab pegol
—Not reported

HAQ-DI, change

adalimumab-adbm (Cyltezo)
—Not reported
certolizumab pegol
-0.5 vs -0.2−0.3 vs placebo400 mg Q4W · wk 24 · n 135NCT01087788
1 other result
  • -0.5 vs -0.2 200 mg Q2W · wk 24 · n 138 · Phase 3 · secondary NCT01087788
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

adalimumab-adbm (Cyltezo): no structured comparison results are available for Psoriatic Arthritis.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. adalimumab-adbm (Cyltezo): 0 of 4 rows · certolizumab pegol: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metriccertolizumab pegol
Dropout rate
—400 mg Q4Wa
NCT01087788 · Phase 3
show 6 more results
—200 mg Q2W
NCT01087788 · Phase 3
—Q2W
NCT03357471 · Phase 3 · registry result, not featured evidence · Crohn's Disease, Psoriatic Arthritis, Rheumatoid Arthritis · phase 3
—Q4W
NCT03357471 · Phase 3 · registry result, not featured evidence · Crohn's Disease, Psoriatic Arthritis, Rheumatoid Arthritis · phase 3
0%400 mg Q4W
NCT04163016 · Phase 1 · registry result, not featured evidence
0%200 mg Q2W
NCT04163016 · Phase 1 · registry result, not featured evidence
0%400 mg Q2W
NCT04163016 · Phase 1 · registry result, not featured evidence
Discontinued due to AEs
—400 mg Q4Wa
NCT01087788 · Phase 3
show 6 more results
—200 mg Q2W
NCT01087788 · Phase 3
—Q2W
NCT03357471 · Phase 3 · registry result, not featured evidence · Crohn's Disease, Psoriatic Arthritis, Rheumatoid Arthritis · phase 3
—Q4W
NCT03357471 · Phase 3 · registry result, not featured evidence · Crohn's Disease, Psoriatic Arthritis, Rheumatoid Arthritis · phase 3
0%400 mg Q4W
NCT04163016 · Phase 1 · registry result, not featured evidence
0%200 mg Q2W
NCT04163016 · Phase 1 · registry result, not featured evidence
0%400 mg Q2W
NCT04163016 · Phase 1 · registry result, not featured evidence
Serious AEs
26.2%400 mg Q4Wa
NCT01087788 · Phase 3
show 6 more results
24.7%200 mg Q2W
NCT01087788 · Phase 3
0%Q2W
NCT03357471 · Phase 3 · registry result, not featured evidence · Crohn's Disease, Psoriatic Arthritis, Rheumatoid Arthritis · phase 3
0%Q4W
NCT03357471 · Phase 3 · registry result, not featured evidence · Crohn's Disease, Psoriatic Arthritis, Rheumatoid Arthritis · phase 3
20%400 mg Q4W
NCT04163016 · Phase 1 · registry result, not featured evidence
26.7%200 mg Q2W
NCT04163016 · Phase 1 · registry result, not featured evidence
—400 mg Q2W
NCT04163016 · Phase 1 · registry result, not featured evidence
Most frequent reported AEs
400 mg Q4Wa
upper respiratory tract infection 25.1%
nasopharyngitis 21.5%
pharyngitis 13.8%
NCT01087788 · Phase 3
show 3 more results
200 mg Q2W
nasopharyngitis 22.7%
upper respiratory tract infection 22.2%
hypertension 15.2%
NCT01087788 · Phase 3
400 mg Q4W
influenza 40%
cystitis 20%
foetal vascular malperfusion 20%
NCT04163016 · Phase 1 · registry result, not featured evidence
200 mg Q2W
covid-19 40%
headache 20%
hypertension 13.3%
NCT04163016 · Phase 1 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for 5 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

certolizumab pegol

ACR20 51.9% (n=135) vs 24.3% (n=136) placebo @ 12wk400 mg Q4W
responder rate · % of participants
NCT01087788 · Phase 3
show 3 more results
56.3% (n=135) vs 23.5% (n=136) placebo @ 24wk400 mg Q4W
NCT01087788 · Phase 3
58% (n=138) vs 24.3% (n=136) placebo @ 12wk200 mg Q2W
NCT01087788 · Phase 3
63.8% (n=138) vs 23.5% (n=136) placebo @ 24wk200 mg Q2W
NCT01087788 · Phase 3
Modified Sharp 25.05 vs 28.92 placebo score @ 24wk400 mg Q4W
absolute change · score
Pre-defined results
NCT01087788 · Phase 3
show 1 more result
11.52 vs 28.92 placebo score @ 24wk200 mg Q2W
Pre-defined results
NCT01087788 · Phase 3
HAQ-DI -0.46 vs -0.19 placebo score @ 24wk400 mg Q4W
absolute change · score
NCT01087788 · Phase 3
show 1 more result
-0.54 vs -0.19 placebo score @ 24wk200 mg Q2W
NCT01087788 · Phase 3
PASI 75 60.5% (n=76) vs 15.1% (n=86) placebo @ 24wk400 mg Q4W
responder rate · % of participants
NCT01087788 · Phase 3
show 1 more result
62.2% (n=90) vs 15.1% (n=86) placebo @ 24wk200 mg Q2W
NCT01087788 · Phase 3
Modified Sharp 0.11 vs 0.32 placebo score @ 48wk400 mg Q4W
absolute change · score
Predefined results: Overall
NCT01087788 · Phase 3
show 1 more result
0.15 vs 0.32 placebo score @ 48wk200 mg Q2W
Predefined results: Overall
NCT01087788 · Phase 3

Psoriasis

Shared mechanism: TNF-alpha · full Psoriasis pipeline

adalimumab-adbm (Cyltezo)

Marketed by Boehringer Ingelheim

Approved in Psoriasismonoclonal antibody
Weak signal

NCT03210259 · Phase 3 · completed

After a 14-week Humira run-in, 238 patients were randomized to switch between Cyltezo and Humira or continue Humira in a double-blind active-controlled period. Both primary pharmacokinetic comparisons met the prespecified equivalence range, but these were drug-level measures rather than direct clinical psoriasis outcomes, so the evidence is moderate. Its registered primary outcomes are pharmacokinetic measures with no comparison, so the evidence grade is capped at weak.

No aligned efficacy figure on record for this race.

certolizumab pegol · Cimzia

Marketed by UCB

Approved in PsoriasisPEGylated anti-TNF Fab' fragment
Reliable signal

NCT02326272 · Phase 3 · completed

This was a randomized, double-blind (quadruple-masked), placebo-controlled trial in 227 adults with moderate-to-severe plaque psoriasis. Both the 200 mg and 400 mg certolizumab pegol doses produced significantly higher rates of skin clearance (PASI75: 81.4% and 82.6% vs 11.6% placebo) and physician-assessed clearance (66.8% and 71.6% vs 2.0% placebo) at week 16, both p<0.0001.

Next expected readout: June 2030 · NCT07352566 (registry estimate)

Reported efficacy

Proportion of Subjects Who Achieve a Psoriasis Activity and Severity Index (PASI75) Response at Week 16; Proportion of Subjects Who Achieve a Physician's Global Assessment (PGA) Clear or Almost Clear (With at Least 2-category Improvement) Response at Week 16: PASI 75 at Week 16 (CIMPASI-1): certolizumab pegol 200mg Q2W 66.5%, 400mg Q2W 75.8%, placebo 6.5% (P<0.0001 for both doses vs placebo). (met)

Result source: NCT02326298

Results for Psoriasis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointadalimumab-adbm (Cyltezo)certolizumab pegol
PASI 75—Not reported82.6% vs 11.6%+71 vs placebo400 mg Q2W · wk 16 · n 87NCT02326272
11 other results
  • 75.8% vs 6.5% 400 mg Q2W · wk 16 · n 88 · Phase 3 · primary NCT02326298
  • 66.7% vs 5% 400 mg Q2W · wk 12 · n 167 · Phase 3 · primary NCT02346240
  • 87.1% vs 7.9% 400 mg Q2W · wk 16 · n 53 · Phase 2/3 · primary NCT03051217
  • 81.4% vs 11.6% 200 mg Q2W · wk 16 · n 91 · Phase 3 · primary NCT02326272
  • 66.5% vs 6.5% 200 mg Q2W · wk 16 · n 95 · Phase 3 · primary NCT02326298
  • 61.3% vs 5% 200 mg Q2W · wk 12 · n 165 · Phase 3 · primary NCT02346240
  • 73% vs 7.9% 200 mg Q2W · wk 16 · n 48 · Phase 2/3 · primary NCT03051217
  • 74.7% vs 3.8% 400 mg Q2W · wk 16 · n 167 · Phase 3 · secondary NCT02346240
  • 68.2% vs 3.8% 200 mg Q2W · wk 16 · n 165 · Phase 3 · secondary NCT02346240
  • 82.8% vs 6.8% 400 mg · wk 12 · n 58 · Phase 2 · primary NCT00245765
  • 74.6% vs 6.8% 200 mg · wk 12 · n 59 · Phase 2 · primary NCT00245765
PASI 90—Not reported55.4% vs 4.5%+50.9 vs placebo400 mg Q2W · wk 16 · n 87NCT02326272
11 other results
  • 43.6% vs 0.4% 400 mg Q2W · wk 16 · n 88 · Phase 3 · secondary NCT02326298
  • 49.1% vs 0.3% 400 mg Q2W · wk 16 · n 167 · Phase 3 · secondary NCT02346240
  • 34% vs 0.2% 400 mg Q2W · wk 12 · n 167 · Phase 3 · secondary NCT02346240
  • 75.7% vs 0.2% 400 mg Q2W · wk 16 · n 53 · Phase 2/3 · secondary NCT03051217
  • 52.6% vs 4.5% 200 mg Q2W · wk 16 · n 91 · Phase 3 · secondary NCT02326272
  • 35.8% vs 0.4% 200 mg Q2W · wk 16 · n 95 · Phase 3 · secondary NCT02326298
  • 39.8% vs 0.3% 200 mg Q2W · wk 16 · n 165 · Phase 3 · secondary NCT02346240
  • 31.2% vs 0.2% 200 mg Q2W · wk 12 · n 165 · Phase 3 · secondary NCT02346240
  • 53.8% vs 0.2% 200 mg Q2W · wk 16 · n 48 · Phase 2/3 · secondary NCT03051217
  • 46.6% vs 1.7% 400 mg · wk 12 · n 58 · Phase 2 · secondary NCT00245765
  • 39% vs 1.7% 200 mg · wk 12 · n 59 · Phase 2 · secondary NCT00245765
PASI 100—Not reported—Not posted · NCT04123795
sPGA 0/1—Not reported57.9% vs 4.2%+53.7 vs placebo400 mg Q2W · wk 16 · n 88NCT02326298
5 other results
  • 47% vs 4.2% 200 mg Q2W · wk 16 · n 95 · Phase 3 · primary NCT02326298
  • 66.7% vs 0% 400 mg Q2W · wk 16 · n 53 · Phase 2/3 · secondary NCT03051217
  • 52.7% vs 0% 200 mg Q2W · wk 16 · n 48 · Phase 2/3 · secondary NCT03051217
  • 72.4% vs 1.7% 400 mg · wk 12 · n 58 · Phase 2 · primary NCT00245765
  • 52.5% vs 1.7% 200 mg · wk 12 · n 59 · Phase 2 · primary NCT00245765
DLQI, change—Not reported-10 vs -3.8−6.2 vs placebo400 mg Q2W · wk 16 · n 87NCT02326272
5 other results
  • -10.2 vs -3.3 400 mg Q2W · wk 16 · n 88 · Phase 3 · secondary NCT02326298
  • -6.8 vs -0.3 400 mg Q2W · wk 16 · n 53 · Phase 2/3 · secondary NCT03051217
  • -10.4 vs -3.8 200 mg Q2W · wk 16 · n 90 · Phase 3 · secondary NCT02326272
  • -9.3 vs -3.3 200 mg Q2W · wk 16 · n 95 · Phase 3 · secondary NCT02326298
  • -6.8 vs -0.3 200 mg Q2W · wk 16 · n 48 · Phase 2/3 · secondary NCT03051217

PASI 75

adalimumab-adbm (Cyltezo)
—Not reported
certolizumab pegol
82.6% vs 11.6%+71 vs placebo400 mg Q2W · wk 16 · n 87NCT02326272
11 other results
  • 75.8% vs 6.5% 400 mg Q2W · wk 16 · n 88 · Phase 3 · primary NCT02326298
  • 66.7% vs 5% 400 mg Q2W · wk 12 · n 167 · Phase 3 · primary NCT02346240
  • 87.1% vs 7.9% 400 mg Q2W · wk 16 · n 53 · Phase 2/3 · primary NCT03051217
  • 81.4% vs 11.6% 200 mg Q2W · wk 16 · n 91 · Phase 3 · primary NCT02326272
  • 66.5% vs 6.5% 200 mg Q2W · wk 16 · n 95 · Phase 3 · primary NCT02326298
  • 61.3% vs 5% 200 mg Q2W · wk 12 · n 165 · Phase 3 · primary NCT02346240
  • 73% vs 7.9% 200 mg Q2W · wk 16 · n 48 · Phase 2/3 · primary NCT03051217
  • 74.7% vs 3.8% 400 mg Q2W · wk 16 · n 167 · Phase 3 · secondary NCT02346240
  • 68.2% vs 3.8% 200 mg Q2W · wk 16 · n 165 · Phase 3 · secondary NCT02346240
  • 82.8% vs 6.8% 400 mg · wk 12 · n 58 · Phase 2 · primary NCT00245765
  • 74.6% vs 6.8% 200 mg · wk 12 · n 59 · Phase 2 · primary NCT00245765

PASI 90

adalimumab-adbm (Cyltezo)
—Not reported
certolizumab pegol
55.4% vs 4.5%+50.9 vs placebo400 mg Q2W · wk 16 · n 87NCT02326272
11 other results
  • 43.6% vs 0.4% 400 mg Q2W · wk 16 · n 88 · Phase 3 · secondary NCT02326298
  • 49.1% vs 0.3% 400 mg Q2W · wk 16 · n 167 · Phase 3 · secondary NCT02346240
  • 34% vs 0.2% 400 mg Q2W · wk 12 · n 167 · Phase 3 · secondary NCT02346240
  • 75.7% vs 0.2% 400 mg Q2W · wk 16 · n 53 · Phase 2/3 · secondary NCT03051217
  • 52.6% vs 4.5% 200 mg Q2W · wk 16 · n 91 · Phase 3 · secondary NCT02326272
  • 35.8% vs 0.4% 200 mg Q2W · wk 16 · n 95 · Phase 3 · secondary NCT02326298
  • 39.8% vs 0.3% 200 mg Q2W · wk 16 · n 165 · Phase 3 · secondary NCT02346240
  • 31.2% vs 0.2% 200 mg Q2W · wk 12 · n 165 · Phase 3 · secondary NCT02346240
  • 53.8% vs 0.2% 200 mg Q2W · wk 16 · n 48 · Phase 2/3 · secondary NCT03051217
  • 46.6% vs 1.7% 400 mg · wk 12 · n 58 · Phase 2 · secondary NCT00245765
  • 39% vs 1.7% 200 mg · wk 12 · n 59 · Phase 2 · secondary NCT00245765

PASI 100

adalimumab-adbm (Cyltezo)
—Not reported
certolizumab pegol
—Not posted · NCT04123795

sPGA 0/1

adalimumab-adbm (Cyltezo)
—Not reported
certolizumab pegol
57.9% vs 4.2%+53.7 vs placebo400 mg Q2W · wk 16 · n 88NCT02326298
5 other results
  • 47% vs 4.2% 200 mg Q2W · wk 16 · n 95 · Phase 3 · primary NCT02326298
  • 66.7% vs 0% 400 mg Q2W · wk 16 · n 53 · Phase 2/3 · secondary NCT03051217
  • 52.7% vs 0% 200 mg Q2W · wk 16 · n 48 · Phase 2/3 · secondary NCT03051217
  • 72.4% vs 1.7% 400 mg · wk 12 · n 58 · Phase 2 · primary NCT00245765
  • 52.5% vs 1.7% 200 mg · wk 12 · n 59 · Phase 2 · primary NCT00245765

DLQI, change

adalimumab-adbm (Cyltezo)
—Not reported
certolizumab pegol
-10 vs -3.8−6.2 vs placebo400 mg Q2W · wk 16 · n 87NCT02326272
5 other results
  • -10.2 vs -3.3 400 mg Q2W · wk 16 · n 88 · Phase 3 · secondary NCT02326298
  • -6.8 vs -0.3 400 mg Q2W · wk 16 · n 53 · Phase 2/3 · secondary NCT03051217
  • -10.4 vs -3.8 200 mg Q2W · wk 16 · n 90 · Phase 3 · secondary NCT02326272
  • -9.3 vs -3.3 200 mg Q2W · wk 16 · n 95 · Phase 3 · secondary NCT02326298
  • -6.8 vs -0.3 200 mg Q2W · wk 16 · n 48 · Phase 2/3 · secondary NCT03051217
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

adalimumab-adbm (Cyltezo): registry results are on file for Psoriasis, but their comparison mappings are not yet available.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. adalimumab-adbm (Cyltezo): 0 of 4 rows · certolizumab pegol: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metriccertolizumab pegol
Dropout rate
—400 mg Q2Wa
NCT02326272 · Phase 3
show 20 more results
—200 mg Q2W
NCT02326272 · Phase 3
—400 mg Q2W
NCT02326298 · Phase 3
—200 mg Q2W
NCT02326298 · Phase 3
—400 mg Q2W
NCT02346240 · Phase 3
—400 mg Q4W
NCT02346240 · Phase 3
—200 mg Q2W
NCT02346240 · Phase 3
—400 mg Q2W
NCT03051217 · Phase 2/3 · registry result, not featured evidence
—400 mg Q4W
NCT03051217 · Phase 2/3 · registry result, not featured evidence
—200 mg Q2W + 400 mg Q4W
NCT03051217 · Phase 2/3 · registry result, not featured evidence · combination
—200 mg Q2W
NCT03051217 · Phase 2/3 · registry result, not featured evidence
—All CZP (SS)
NCT03051217 · Phase 2/3 · registry result, not featured evidence
5.4%400 mg
NCT00329303 · Phase 2 · registry result, not featured evidence
5.9%200 mg
NCT00329303 · Phase 2 · registry result, not featured evidence
13.8%400 mg
NCT00245765 · Phase 2 · registry result, not featured evidence
—400 mg
NCT00245765 · Phase 2 · registry result, not featured evidence
23.7%200 mg
NCT00245765 · Phase 2 · registry result, not featured evidence
—200 mg
NCT00245765 · Phase 2 · registry result, not featured evidence
0%400 mg Q2W
NCT04163016 · Phase 1 · registry result, not featured evidence
0%400 mg Q4W
NCT04163016 · Phase 1 · registry result, not featured evidence
0%200 mg Q2W
NCT04163016 · Phase 1 · registry result, not featured evidence
Discontinued due to AEs
—400 mg Q2Wa
NCT02326272 · Phase 3
show 20 more results
—200 mg Q2W
NCT02326272 · Phase 3
—400 mg Q2W
NCT02326298 · Phase 3
—200 mg Q2W
NCT02326298 · Phase 3
—400 mg Q2W
NCT02346240 · Phase 3
—400 mg Q4W
NCT02346240 · Phase 3
—200 mg Q2W
NCT02346240 · Phase 3
—400 mg Q2W
NCT03051217 · Phase 2/3 · registry result, not featured evidence
—400 mg Q4W
NCT03051217 · Phase 2/3 · registry result, not featured evidence
—200 mg Q2W + 400 mg Q4W
NCT03051217 · Phase 2/3 · registry result, not featured evidence · combination
—200 mg Q2W
NCT03051217 · Phase 2/3 · registry result, not featured evidence
—All CZP (SS)
NCT03051217 · Phase 2/3 · registry result, not featured evidence
—400 mg
NCT00329303 · Phase 2 · registry result, not featured evidence
—200 mg
NCT00329303 · Phase 2 · registry result, not featured evidence
0%400 mg
NCT00245765 · Phase 2 · registry result, not featured evidence
—400 mg
NCT00245765 · Phase 2 · registry result, not featured evidence
1.7%200 mg
NCT00245765 · Phase 2 · registry result, not featured evidence
—200 mg
NCT00245765 · Phase 2 · registry result, not featured evidence
0%400 mg Q2W
NCT04163016 · Phase 1 · registry result, not featured evidence
0%400 mg Q4W
NCT04163016 · Phase 1 · registry result, not featured evidence
0%200 mg Q2W
NCT04163016 · Phase 1 · registry result, not featured evidence
Serious AEs
8.1%400 mg Q2Wa
NCT02326272 · Phase 3
show 20 more results
14.1%200 mg Q2W
NCT02326272 · Phase 3
11.4%400 mg Q2W
NCT02326298 · Phase 3
7.4%200 mg Q2W
NCT02326298 · Phase 3
12.4%400 mg Q2W
NCT02346240 · Phase 3
11.4%400 mg Q4W
NCT02346240 · Phase 3
9.1%200 mg Q2W
NCT02346240 · Phase 3
9.4%400 mg Q2W
NCT03051217 · Phase 2/3 · registry result, not featured evidence
0%400 mg Q4W
NCT03051217 · Phase 2/3 · registry result, not featured evidence
2.8%200 mg Q2W + 400 mg Q4W
NCT03051217 · Phase 2/3 · registry result, not featured evidence · combination
2.8%200 mg Q2W
NCT03051217 · Phase 2/3 · registry result, not featured evidence
6.6%All CZP (SS)
NCT03051217 · Phase 2/3 · registry result, not featured evidence
0%400 mg
NCT00329303 · Phase 2 · registry result, not featured evidence
0%200 mg
NCT00329303 · Phase 2 · registry result, not featured evidence
—400 mg
NCT00245765 · Phase 2 · registry result, not featured evidence
8.8%400 mg
NCT00245765 · Phase 2 · registry result, not featured evidence
—200 mg
NCT00245765 · Phase 2 · registry result, not featured evidence
3.3%200 mg
NCT00245765 · Phase 2 · registry result, not featured evidence
—400 mg Q2W
NCT04163016 · Phase 1 · registry result, not featured evidence
20%400 mg Q4W
NCT04163016 · Phase 1 · registry result, not featured evidence
26.7%200 mg Q2W
NCT04163016 · Phase 1 · registry result, not featured evidence
Most frequent reported AEs
400 mg Q2Wa
nasopharyngitis 23.5%
upper respiratory tract infection 12.1%
psoriasis 8.1%
NCT02326272 · Phase 3
show 17 more results
200 mg Q2W
nasopharyngitis 19.4%
upper respiratory tract infection 11.2%
sinusitis 7.6%
NCT02326272 · Phase 3
400 mg Q2W
nasopharyngitis 30.5%
upper respiratory tract infection 15.6%
headache 8.4%
NCT02326298 · Phase 3
200 mg Q2W
nasopharyngitis 28.7%
upper respiratory tract infection 11.2%
arthralgia 7.4%
NCT02326298 · Phase 3
400 mg Q2W
nasopharyngitis 16% (placebo 11.7%)
upper respiratory tract infection 10.9% (placebo 10.2%)
hypertension 5.8% (placebo 5.5%)
NCT02346240 · Phase 3
400 mg Q4W
arthralgia 6.8% (placebo 2.3%)
blood creatine phosphokinase increased 6.8% (placebo 1.6%)
nasopharyngitis 6.8% (placebo 11.7%)
NCT02346240 · Phase 3
200 mg Q2W
nasopharyngitis 15% (placebo 11.7%)
upper respiratory tract infection 10.2% (placebo 10.2%)
viral upper respiratory tract infection 6.2% (placebo 1.6%)
NCT02346240 · Phase 3
400 mg Q2W
nasopharyngitis 43.8% (placebo 23.1%)
psoriasis 7.8% (placebo 23.1%)
dermatitis contact 6.3% (placebo 0%)
NCT03051217 · Phase 2/3 · registry result, not featured evidence
400 mg Q4W
nasopharyngitis 30% (placebo 23.1%)
back pain 10% (placebo 0%)
dental caries 10% (placebo 0%)
NCT03051217 · Phase 2/3 · registry result, not featured evidence
200 mg Q2W + 400 mg Q4W
nasopharyngitis 34.7% (placebo 23.1%)
psoriasis 11.1% (placebo 23.1%)
eczema 6.9% (placebo 0%)
NCT03051217 · Phase 2/3 · registry result, not featured evidence · combination
200 mg Q2W
nasopharyngitis 31.9% (placebo 23.1%)
psoriasis 11.1% (placebo 23.1%)
eczema 6.9% (placebo 0%)
NCT03051217 · Phase 2/3 · registry result, not featured evidence
nasopharyngitis 43.4% (placebo 23.1%)
psoriasis 10.7% (placebo 23.1%)
eczema 7.4% (placebo 0%)
NCT03051217 · Phase 2/3 · registry result, not featured evidence
400 mg
headache 8.1%
nasopharyngitis 8.1%
asthenia 5.4%
NCT00329303 · Phase 2 · registry result, not featured evidence
200 mg
nasopharyngitis 14.7%
psoriasis 11.8%
arthralgia 5.9%
NCT00329303 · Phase 2 · registry result, not featured evidence
400 mg
nasopharyngitis 21.1% (placebo 17.2%)
headache 14% (placebo 15.5%)
bronchitis 7% (placebo 5.2%)
NCT00245765 · Phase 2 · registry result, not featured evidence
200 mg
headache 21.7% (placebo 15.5%)
pruritus 11.7% (placebo 6.9%)
arthralgia 8.3% (placebo 3.4%)
NCT00245765 · Phase 2 · registry result, not featured evidence
400 mg Q4W
influenza 40%
cystitis 20%
foetal vascular malperfusion 20%
NCT04163016 · Phase 1 · registry result, not featured evidence
200 mg Q2W
covid-19 40%
headache 20%
hypertension 13.3%
NCT04163016 · Phase 1 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

certolizumab pegol

PASI 75 82.6% (n=87) vs 11.6% (n=49) placebo @ 16wk400 mg Q2W
responder rate · % of participants
NCT02326272 · Phase 3
show 11 more results
75.8% (n=88) vs 6.5% (n=51) placebo @ 16wk400 mg Q2W
NCT02326298 · Phase 3
66.7% (n=167) vs 5% (n=57) placebo @ 12wk400 mg Q2W
NCT02346240 · Phase 3
74.7% (n=167) vs 3.8% (n=57) placebo @ 16wk400 mg Q2W
NCT02346240 · Phase 3
87.1% (n=53) vs 7.9% (n=26) placebo @ 16wk400 mg Q2W
NCT03051217 · Phase 2/3 · registry result, not featured evidence
82.8% (n=58) vs 6.8% (n=59) placebo @ 12wk400 mg
NCT00245765 · Phase 2 · registry result, not featured evidence
81.4% (n=91) vs 11.6% (n=49) placebo @ 16wk200 mg Q2W
NCT02326272 · Phase 3
66.5% (n=95) vs 6.5% (n=51) placebo @ 16wk200 mg Q2W
NCT02326298 · Phase 3
61.3% (n=165) vs 5% (n=57) placebo @ 12wk200 mg Q2W
NCT02346240 · Phase 3
68.2% (n=165) vs 3.8% (n=57) placebo @ 16wk200 mg Q2W
NCT02346240 · Phase 3
73% (n=48) vs 7.9% (n=26) placebo @ 16wk200 mg Q2W
NCT03051217 · Phase 2/3 · registry result, not featured evidence
74.6% (n=59) vs 6.8% (n=59) placebo @ 12wk200 mg
NCT00245765 · Phase 2 · registry result, not featured evidence
PGA Clear or Almost Clear 2pt Improvement 71.6% (n=87) vs 2% (n=49) placebo @ 16wk400 mg Q2W
responder rate · % of participants
NCT02326272 · Phase 3
show 1 more result
66.8% (n=91) vs 2% (n=49) placebo @ 16wk200 mg Q2W
NCT02326272 · Phase 3
PASI 90 55.4% (n=87) vs 4.5% (n=49) placebo @ 16wk400 mg Q2W
responder rate · % of participants
NCT02326272 · Phase 3
show 11 more results
43.6% (n=88) vs 0.4% (n=51) placebo @ 16wk400 mg Q2W
NCT02326298 · Phase 3
34% (n=167) vs 0.2% (n=57) placebo @ 12wk400 mg Q2W
NCT02346240 · Phase 3
49.1% (n=167) vs 0.3% (n=57) placebo @ 16wk400 mg Q2W
NCT02346240 · Phase 3
75.7% (n=53) vs 0.2% (n=26) placebo @ 16wk400 mg Q2W
NCT03051217 · Phase 2/3 · registry result, not featured evidence
46.6% (n=58) vs 1.7% (n=59) placebo @ 12wk400 mg
NCT00245765 · Phase 2 · registry result, not featured evidence
52.6% (n=91) vs 4.5% (n=49) placebo @ 16wk200 mg Q2W
NCT02326272 · Phase 3
35.8% (n=95) vs 0.4% (n=51) placebo @ 16wk200 mg Q2W
NCT02326298 · Phase 3
31.2% (n=165) vs 0.2% (n=57) placebo @ 12wk200 mg Q2W
NCT02346240 · Phase 3
39.8% (n=165) vs 0.3% (n=57) placebo @ 16wk200 mg Q2W
NCT02346240 · Phase 3
53.8% (n=48) vs 0.2% (n=26) placebo @ 16wk200 mg Q2W
NCT03051217 · Phase 2/3 · registry result, not featured evidence
39% (n=59) vs 1.7% (n=59) placebo @ 12wk200 mg
NCT00245765 · Phase 2 · registry result, not featured evidence
PGA Clear or Almost Clear 2pt Improvement 66.6% (n=87) @ 48wk400 mg Q2W
responder rate · % of participants
No placebo or comparator arm
NCT02326272 · Phase 3
show 1 more result
72.6% (n=91) @ 48wk200 mg Q2W
NCT02326272 · Phase 3
PASI 75 81.3% (n=87) @ 48wk400 mg Q2W
responder rate · % of participants
No placebo or comparator arm
NCT02326272 · Phase 3
show 7 more results
87.1% (n=88) @ 48wk400 mg Q2W
NCT02326298 · Phase 3
86.5% (n=37) @ 12wk400 mg
NCT00329303 · Phase 2 · registry result, not featured evidence
75.7% (n=37) @ 12wk400 mg
NCT00329303 · Phase 2 · registry result, not featured evidence
78.7% (n=91) @ 48wk200 mg Q2W
NCT02326272 · Phase 3
67.2% (n=95) @ 48wk200 mg Q2W
NCT02326298 · Phase 3
67.6% (n=34) @ 12wk200 mg
NCT00329303 · Phase 2 · registry result, not featured evidence
50% (n=34) @ 12wk200 mg
NCT00329303 · Phase 2 · registry result, not featured evidence
DLQI -10 vs -3.8 placebo score @ 16wk400 mg Q2W
absolute change · score
NCT02326272 · Phase 3
show 5 more results
-10.2 vs -3.3 placebo score @ 16wk400 mg Q2W
NCT02326298 · Phase 3
-6.8 vs -0.3 placebo score @ 16wk400 mg Q2W
NCT03051217 · Phase 2/3 · registry result, not featured evidence
-10.4 vs -3.8 placebo score @ 16wk200 mg Q2W
NCT02326272 · Phase 3
-9.3 vs -3.3 placebo score @ 16wk200 mg Q2W
NCT02326298 · Phase 3
-6.8 vs -0.3 placebo score @ 16wk200 mg Q2W
NCT03051217 · Phase 2/3 · registry result, not featured evidence
sPGA 0/1 57.9% (n=88) vs 4.2% (n=51) placebo @ 16wk400 mg Q2W
responder rate · % of participants
NCT02326298 · Phase 3
show 5 more results
66.7% (n=53) vs 0% (n=26) placebo @ 16wk400 mg Q2W
NCT03051217 · Phase 2/3 · registry result, not featured evidence
72.4% (n=58) vs 1.7% (n=59) placebo @ 12wk400 mg
NCT00245765 · Phase 2 · registry result, not featured evidence
47% (n=95) vs 4.2% (n=51) placebo @ 16wk200 mg Q2W
NCT02326298 · Phase 3
52.7% (n=48) vs 0% (n=26) placebo @ 16wk200 mg Q2W
NCT03051217 · Phase 2/3 · registry result, not featured evidence
52.5% (n=59) vs 1.7% (n=59) placebo @ 12wk200 mg
NCT00245765 · Phase 2 · registry result, not featured evidence
sPGA 0/1 69.5% (n=88) @ 48wk400 mg Q2W
responder rate · % of participants
No placebo or comparator arm
NCT02326298 · Phase 3
show 3 more results
56.8% (n=37) @ 12wk400 mg
NCT00329303 · Phase 2 · registry result, not featured evidence
52.7% (n=95) @ 48wk200 mg Q2W
NCT02326298 · Phase 3
52.9% (n=34) @ 12wk200 mg
NCT00329303 · Phase 2 · registry result, not featured evidence
PGA 0 1 2pt Improvement 50.3% (n=167) vs 1.9% (n=57) placebo @ 12wk400 mg Q2W
responder rate · % of participants
NCT02346240 · Phase 3
show 3 more results
58.4% (n=167) vs 3.4% (n=57) placebo @ 16wk400 mg Q2W
NCT02346240 · Phase 3
39.8% (n=165) vs 1.9% (n=57) placebo @ 12wk200 mg Q2W
NCT02346240 · Phase 3
48.3% (n=165) vs 3.4% (n=57) placebo @ 16wk200 mg Q2W
NCT02346240 · Phase 3
PASI-75 Response Maintenance 88.6% (n=44) vs 100% (n=2) placebo @ 48wk400 mg Q4W
responder rate · % of participants
NCT02346240 · Phase 3
show 4 more results
98% (n=49) vs 100% (n=2) placebo @ 48wk400 mg Q2W
NCT02346240 · Phase 3
82% (n=50) vs 100% (n=2) placebo @ 48wk200 mg Q2W
NCT02346240 · Phase 3
79.5% (n=44) vs 100% (n=2) placebo @ 48wk200 mg Q2W
NCT02346240 · Phase 3
80% (n=50) vs 100% (n=2) placebo @ 48wk200 mg Q2W
NCT02346240 · Phase 3
Itch NRS -4 vs 0.2 placebo score @ 16wk400 mg Q2W
absolute change · score
NCT03051217 · Phase 2/3 · registry result, not featured evidence
show 1 more result
-2.9 vs 0.2 placebo score @ 16wk200 mg Q2W
NCT03051217 · Phase 2/3 · registry result, not featured evidence
PASI 50 89.2% (n=37) @ 12wk400 mg
responder rate · % of participants
No placebo or comparator arm
NCT00329303 · Phase 2 · registry result, not featured evidence
show 3 more results
89.2% (n=37) @ 12wk400 mg
NCT00329303 · Phase 2 · registry result, not featured evidence
76.5% (n=34) @ 12wk200 mg
NCT00329303 · Phase 2 · registry result, not featured evidence
67.6% (n=34) @ 12wk200 mg
NCT00329303 · Phase 2 · registry result, not featured evidence

+ 11 further endpoints in the CSV export.

Rheumatoid Arthritis

Shared mechanism: TNF-alpha · full Rheumatoid Arthritis pipeline

adalimumab-adbm (Cyltezo)

Marketed by Boehringer Ingelheim

Approved in Rheumatoid Arthritismonoclonal antibody
Reliable signal

NCT02137226 · Phase 3 · completed

The 645-participant study was randomized, double-blind, and active-controlled against US-licensed Humira, with ACR20 response as the primary clinical endpoint. The prespecified equivalence margins were met at both Week 12 and Week 24, so the comparison supports equivalent clinical response between BI 695501 and Humira.

No aligned efficacy figure on record for this race.

certolizumab pegol · Cimzia

Marketed by UCB

Approved in Rheumatoid ArthritisPEGylated anti-TNF Fab' fragment
Weak signal

NCT03357471 · Phase 3 · completed

Allocation was NON_RANDOMIZED with masking NONE and no control/comparator arm (two parallel non-randomized dosing groups, not randomized treatment vs. control), so this defaults to 'weak' per the design test regardless of the very high reported success rates; the primary endpoint is also a device-usability surrogate rather than a hard clinical/endoscopic outcome.

Next expected readout: March 2028 · NCT03414502 (registry estimate)

Reported efficacy

Percentage of Subjects Able to Self-administer Safe and Effective Injections Using the e-Device at Visit 2 (Visit 2 (Week 2 for Q2W; Week 4 for Q4W)): Percentage of Subjects Able to Self-administer Safe and Effective Injections Using the e-Device at Visit 2 (Visit 2 (Week 2 for Q2W; Week 4 for Q4W)): Certolizumab Pegol Q2W Injection by e-Device (SS) 100 percentage of subjects (95% CI 91.3 to 100) | Certolizumab Pegol Q4W Injection by e-Device (SS) 96.88 percentage of subjects (95% CI 86 to 99.8)

Result source: NCT03357471

Results for Rheumatoid Arthritis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointadalimumab-adbm (Cyltezo)certolizumab pegol
ACR20—Not reported54.8% vs 23.9%+30.9 vs placebowk 24 · n 312NCT02151851
21 other results
  • 51.1% vs 25.9% wk 12 · n 851 · Phase 3 · primary NCT00717236
  • 77.6% vs 28.6% 400 mg · wk 12 · n 85 · Phase 2/3 · primary NCT00791999
  • 67.2% vs 14.9% 200mg · wk 12 · n 116 · Phase 3 · primary NCT00791921
  • 76.8% vs 28.6% 200 mg · wk 12 · n 82 · Phase 2/3 · primary NCT00791999
  • 62.5% vs 28.6% 100 mg · wk 12 · n 72 · Phase 2/3 · primary NCT00791999
  • 66.7% vs 27.5% 200mg · wk 24 · n 81 · Phase 3 · primary NCT00993317
  • 69% vs 61.5% wk 52 · n 655 · Phase 3 · secondary NCT01519791
  • 71.8% vs 24.7% 400 mg · wk 24 · n 85 · Phase 2/3 · secondary NCT00791999
  • 36.5% vs 15.3% 200 mg · wk 24 · n 96 · Phase 3 · secondary NCT00674362
  • 63.8% vs 11.4% 200mg · wk 24 · n 116 · Phase 3 · secondary NCT00791921
  • 73.2% vs 24.7% 200 mg · wk 24 · n 82 · Phase 2/3 · secondary NCT00791999
  • 61.1% vs 24.7% 100 mg · wk 24 · n 72 · Phase 2/3 · secondary NCT00791999
  • 64.2% vs 37.5% 200mg · wk 12 · n 81 · Phase 3 · secondary NCT00993317
  • 86.5% vs 74.7% Q4W · wk 104 · n 126 · Phase 3 · secondary NCT01521923
  • 73.8% vs 74.7% Q2W · wk 104 · n 84 · Phase 3 · secondary NCT01521923
  • 65.2% vs 44.9% 400 mg · wk 34 · n 69 · Phase 4 · primary NCT00580840
  • 67.1% vs 44.9% 200 mg · wk 34 · n 70 · Phase 4 · primary NCT00580840
  • 61.5% vs 0% wk 12 · n 26 · Phase 4 · primary NCT01147341
  • 69.2% vs 71.4% wk 12 · n 454 · Phase 4 · primary NCT01500278
  • 54.5% vs 62.5% wk 24 · n 22 · Phase 4 · secondary NCT01147341
  • 64.5% vs 60.8% wk 6 · n 454 · Phase 4 · secondary NCT01500278
ACR50—Not reported61.8% vs 52.6%+9.2 vs placebowk 52 · n 655NCT01519791
11 other results
  • 80.2% vs 68.4% Q4W · wk 104 · n 126 · Phase 3 · secondary NCT01521923
  • 36.5% vs 7.1% wk 24 · n 312 · Phase 3 · secondary NCT02151851
  • 26.6% vs 9.9% wk 12 · n 851 · Phase 3 · secondary NCT00717236
  • 20.8% vs 7.1% 200 mg · wk 24 · n 96 · Phase 3 · secondary NCT00674362
  • 43.2% vs 20% 200mg · wk 24 · n 81 · Phase 3 · secondary NCT00993317
  • 25.9% vs 12.5% 200mg · wk 12 · n 81 · Phase 3 · secondary NCT00993317
  • 71.4% vs 68.4% Q2W · wk 104 · n 84 · Phase 3 · secondary NCT01521923
  • 52.2% vs 30.4% 400 mg · wk 34 · n 69 · Phase 4 · secondary NCT00580840
  • 50% vs 30.4% 200 mg · wk 34 · n 70 · Phase 4 · secondary NCT00580840
  • 27.3% vs 37.5% wk 24 · n 22 · Phase 4 · secondary NCT01147341
  • 19.2% vs 0% wk 12 · n 26 · Phase 4 · secondary NCT01147341
ACR70—Not reported51.3% vs 39.9%+11.4 vs placebowk 52 · n 655NCT01519791
9 other results
  • 12.9% vs 2.8% wk 12 · n 851 · Phase 3 · secondary NCT00717236
  • 13.6% vs 0% 200mg · wk 12 · n 81 · Phase 3 · secondary NCT00993317
  • 70.6% vs 60.8% Q4W · wk 104 · n 126 · Phase 3 · secondary NCT01521923
  • 16.7% vs 2.7% wk 24 · n 312 · Phase 3 · secondary NCT02151851
  • 9.4% vs 3.1% 200 mg · wk 24 · n 96 · Phase 3 · secondary NCT00674362
  • 17.3% vs 2.5% 200mg · wk 24 · n 81 · Phase 3 · secondary NCT00993317
  • 63.1% vs 60.8% Q2W · wk 104 · n 84 · Phase 3 · secondary NCT01521923
  • 37.7% vs 15.9% 400 mg · wk 34 · n 69 · Phase 4 · secondary NCT00580840
  • 30% vs 15.9% 200 mg · wk 34 · n 70 · Phase 4 · secondary NCT00580840
DAS28-CRP remission—Not reported16% vs 5.7%+10.3 vs placebowk 12 · n 851NCT00717236
HAQ-DI, change—Not reported-1.0 vs -0.8−0.2 vs placebowk 52 · n 645NCT01519791
8 other results
  • -0.5 vs -0.2 wk 24 · n 306 · Phase 3 · secondary NCT02151851
  • -0.4 vs -0.2 wk 12 · n 826 · Phase 3 · secondary NCT00717236
  • -0.3 vs -0.0 200 mg · wk 24 · n 91 · Phase 3 · secondary NCT00674362
  • -0.5 vs -0.2 200mg · wk 24 · n 81 · Phase 3 · secondary NCT00993317
  • -0.5 vs -0.8 wk 16 · n 23 · Phase 3 · secondary NCT01235598
  • -0.6 vs -0.4 400 mg · wk 34 · n 69 · Phase 4 · secondary NCT00580840
  • -0.7 vs -0.4 200 mg · wk 34 · n 70 · Phase 4 · secondary NCT00580840
  • -0.6 vs -0.7 wk 104 · n 454 · Phase 4 · secondary NCT01500278
Modified Sharp score, change—Not reported0.4 vs 1.6−1.2 vs placebowk 52 · n 158NCT01451203
6 other results
  • 0.2 vs 1.8 wk 52 · n 528 · Phase 3 · secondary NCT01519791
  • 0 vs 0 Q4W · wk 104 · n 113 · Phase 3 · secondary NCT01521923
  • 0 vs 0 Q2W · wk 104 · n 72 · Phase 3 · secondary NCT01521923
  • 0 vs 0 Q4W · wk 104 · n 113 · Phase 3 · secondary NCT01521923
  • 0 vs 0 Q2W · wk 104 · n 72 · Phase 3 · secondary NCT01521923
  • 0.3 vs 0.9 wk 24 · n 158 · Phase 3 · secondary NCT01451203

ACR20

adalimumab-adbm (Cyltezo)
—Not reported
certolizumab pegol
54.8% vs 23.9%+30.9 vs placebowk 24 · n 312NCT02151851
21 other results
  • 51.1% vs 25.9% wk 12 · n 851 · Phase 3 · primary NCT00717236
  • 77.6% vs 28.6% 400 mg · wk 12 · n 85 · Phase 2/3 · primary NCT00791999
  • 67.2% vs 14.9% 200mg · wk 12 · n 116 · Phase 3 · primary NCT00791921
  • 76.8% vs 28.6% 200 mg · wk 12 · n 82 · Phase 2/3 · primary NCT00791999
  • 62.5% vs 28.6% 100 mg · wk 12 · n 72 · Phase 2/3 · primary NCT00791999
  • 66.7% vs 27.5% 200mg · wk 24 · n 81 · Phase 3 · primary NCT00993317
  • 69% vs 61.5% wk 52 · n 655 · Phase 3 · secondary NCT01519791
  • 71.8% vs 24.7% 400 mg · wk 24 · n 85 · Phase 2/3 · secondary NCT00791999
  • 36.5% vs 15.3% 200 mg · wk 24 · n 96 · Phase 3 · secondary NCT00674362
  • 63.8% vs 11.4% 200mg · wk 24 · n 116 · Phase 3 · secondary NCT00791921
  • 73.2% vs 24.7% 200 mg · wk 24 · n 82 · Phase 2/3 · secondary NCT00791999
  • 61.1% vs 24.7% 100 mg · wk 24 · n 72 · Phase 2/3 · secondary NCT00791999
  • 64.2% vs 37.5% 200mg · wk 12 · n 81 · Phase 3 · secondary NCT00993317
  • 86.5% vs 74.7% Q4W · wk 104 · n 126 · Phase 3 · secondary NCT01521923
  • 73.8% vs 74.7% Q2W · wk 104 · n 84 · Phase 3 · secondary NCT01521923
  • 65.2% vs 44.9% 400 mg · wk 34 · n 69 · Phase 4 · primary NCT00580840
  • 67.1% vs 44.9% 200 mg · wk 34 · n 70 · Phase 4 · primary NCT00580840
  • 61.5% vs 0% wk 12 · n 26 · Phase 4 · primary NCT01147341
  • 69.2% vs 71.4% wk 12 · n 454 · Phase 4 · primary NCT01500278
  • 54.5% vs 62.5% wk 24 · n 22 · Phase 4 · secondary NCT01147341
  • 64.5% vs 60.8% wk 6 · n 454 · Phase 4 · secondary NCT01500278

ACR50

adalimumab-adbm (Cyltezo)
—Not reported
certolizumab pegol
61.8% vs 52.6%+9.2 vs placebowk 52 · n 655NCT01519791
11 other results
  • 80.2% vs 68.4% Q4W · wk 104 · n 126 · Phase 3 · secondary NCT01521923
  • 36.5% vs 7.1% wk 24 · n 312 · Phase 3 · secondary NCT02151851
  • 26.6% vs 9.9% wk 12 · n 851 · Phase 3 · secondary NCT00717236
  • 20.8% vs 7.1% 200 mg · wk 24 · n 96 · Phase 3 · secondary NCT00674362
  • 43.2% vs 20% 200mg · wk 24 · n 81 · Phase 3 · secondary NCT00993317
  • 25.9% vs 12.5% 200mg · wk 12 · n 81 · Phase 3 · secondary NCT00993317
  • 71.4% vs 68.4% Q2W · wk 104 · n 84 · Phase 3 · secondary NCT01521923
  • 52.2% vs 30.4% 400 mg · wk 34 · n 69 · Phase 4 · secondary NCT00580840
  • 50% vs 30.4% 200 mg · wk 34 · n 70 · Phase 4 · secondary NCT00580840
  • 27.3% vs 37.5% wk 24 · n 22 · Phase 4 · secondary NCT01147341
  • 19.2% vs 0% wk 12 · n 26 · Phase 4 · secondary NCT01147341

ACR70

adalimumab-adbm (Cyltezo)
—Not reported
certolizumab pegol
51.3% vs 39.9%+11.4 vs placebowk 52 · n 655NCT01519791
9 other results
  • 12.9% vs 2.8% wk 12 · n 851 · Phase 3 · secondary NCT00717236
  • 13.6% vs 0% 200mg · wk 12 · n 81 · Phase 3 · secondary NCT00993317
  • 70.6% vs 60.8% Q4W · wk 104 · n 126 · Phase 3 · secondary NCT01521923
  • 16.7% vs 2.7% wk 24 · n 312 · Phase 3 · secondary NCT02151851
  • 9.4% vs 3.1% 200 mg · wk 24 · n 96 · Phase 3 · secondary NCT00674362
  • 17.3% vs 2.5% 200mg · wk 24 · n 81 · Phase 3 · secondary NCT00993317
  • 63.1% vs 60.8% Q2W · wk 104 · n 84 · Phase 3 · secondary NCT01521923
  • 37.7% vs 15.9% 400 mg · wk 34 · n 69 · Phase 4 · secondary NCT00580840
  • 30% vs 15.9% 200 mg · wk 34 · n 70 · Phase 4 · secondary NCT00580840

DAS28-CRP remission

adalimumab-adbm (Cyltezo)
—Not reported
certolizumab pegol
16% vs 5.7%+10.3 vs placebowk 12 · n 851NCT00717236

HAQ-DI, change

adalimumab-adbm (Cyltezo)
—Not reported
certolizumab pegol
-1.0 vs -0.8−0.2 vs placebowk 52 · n 645NCT01519791
8 other results
  • -0.5 vs -0.2 wk 24 · n 306 · Phase 3 · secondary NCT02151851
  • -0.4 vs -0.2 wk 12 · n 826 · Phase 3 · secondary NCT00717236
  • -0.3 vs -0.0 200 mg · wk 24 · n 91 · Phase 3 · secondary NCT00674362
  • -0.5 vs -0.2 200mg · wk 24 · n 81 · Phase 3 · secondary NCT00993317
  • -0.5 vs -0.8 wk 16 · n 23 · Phase 3 · secondary NCT01235598
  • -0.6 vs -0.4 400 mg · wk 34 · n 69 · Phase 4 · secondary NCT00580840
  • -0.7 vs -0.4 200 mg · wk 34 · n 70 · Phase 4 · secondary NCT00580840
  • -0.6 vs -0.7 wk 104 · n 454 · Phase 4 · secondary NCT01500278

Modified Sharp score, change

adalimumab-adbm (Cyltezo)
—Not reported
certolizumab pegol
0.4 vs 1.6−1.2 vs placebowk 52 · n 158NCT01451203
6 other results
  • 0.2 vs 1.8 wk 52 · n 528 · Phase 3 · secondary NCT01519791
  • 0 vs 0 Q4W · wk 104 · n 113 · Phase 3 · secondary NCT01521923
  • 0 vs 0 Q2W · wk 104 · n 72 · Phase 3 · secondary NCT01521923
  • 0 vs 0 Q4W · wk 104 · n 113 · Phase 3 · secondary NCT01521923
  • 0 vs 0 Q2W · wk 104 · n 72 · Phase 3 · secondary NCT01521923
  • 0.3 vs 0.9 wk 24 · n 158 · Phase 3 · secondary NCT01451203
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

adalimumab-adbm (Cyltezo): registry results are on file for Rheumatoid Arthritis, but their comparison mappings are not yet available.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. adalimumab-adbm (Cyltezo): 0 of 4 rows · certolizumab pegol: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metriccertolizumab pegol
Dropout rate
—Q2Wa
NCT03357471 · Phase 3 · Crohn's Disease, Psoriatic Arthritis, Rheumatoid Arthritis · phase 3
show 40 more results
—Q4W
NCT03357471 · Phase 3 · Crohn's Disease, Psoriatic Arthritis, Rheumatoid Arthritis · phase 3
41.3%
NCT00175877 · Phase 3
66.7%
NCT02451748 · Phase 4 · registry result, not featured evidence · combination
—
NCT01500278 · Phase 4 · registry result, not featured evidence · combination
31.1%
NCT01443364 · Phase 4 · registry result, not featured evidence
47.7%CDAI to Assess Response to Cimzia
NCT01255761 · Phase 4 · registry result, not featured evidence
49.3%RAPID3 to Assess Response to Cimzi
NCT01255761 · Phase 4 · registry result, not featured evidence
3.7%
NCT01147341 · Phase 4 · registry result, not featured evidence
—400 mg
NCT00580840 · Phase 4 · registry result, not featured evidence · combination
—200 mg
NCT00580840 · Phase 4 · registry result, not featured evidence · combination
2.7%Cimzia
NCT00993668 · Phase 4 · registry result, not featured evidence
—Cimzia (Single Blind)
NCT00993668 · Phase 4 · registry result, not featured evidence
2.4%Open-label Cimzia (Cimzia in Feede
NCT02319642 · Phase 3 · registry result, not featured evidence
4.2%Open-label Cimzia (Placebo in Feed
NCT02319642 · Phase 3 · registry result, not featured evidence
—
NCT02151851 · Phase 3 · registry result, not featured evidence · combination
55.8%
NCT01519791 · Phase 3 · registry result, not featured evidence · combination
15.7%Q2W
NCT01521923 · Phase 3 · registry result, not featured evidence · combination
11.8%Q4W
NCT01521923 · Phase 3 · registry result, not featured evidence · combination
31.1%
NCT01451203 · Phase 3 · registry result, not featured evidence · combination
30.2%400 mg
NCT00850343 · Phase 3 · registry result, not featured evidence
25%200 mg
NCT00850343 · Phase 3 · registry result, not featured evidence
32.6%200 mg
NCT00850343 · Phase 3 · registry result, not featured evidence
41.8%200 mg
NCT00850343 · Phase 3 · registry result, not featured evidence
14.3%
NCT01235598 · Phase 3 · registry result, not featured evidence
26.7%
NCT00843778 · Phase 3 · registry result, not featured evidence
8.3%
NCT01374971 · Phase 3 · registry result, not featured evidence
39%
NCT00160641 · Phase 3 · registry result, not featured evidence
29.4%200mg
NCT00993317 · Phase 3 · registry result, not featured evidence · combination
8.3%
NCT00753454 · Phase 3 · registry result, not featured evidence
9.4%
NCT00717236 · Phase 3 · registry result, not featured evidence
58.5%
NCT00160693 · Phase 3 · registry result, not featured evidence
12.5%200 mg
NCT00674362 · Phase 3 · registry result, not featured evidence
29.3%200mg
NCT00791921 · Phase 3 · registry result, not featured evidence
23.5%400 mg
NCT00791999 · Phase 2/3 · registry result, not featured evidence
19.5%200 mg
NCT00791999 · Phase 2/3 · registry result, not featured evidence
29.2%100 mg
NCT00791999 · Phase 2/3 · registry result, not featured evidence
0%400 mg Q2W
NCT04163016 · Phase 1 · registry result, not featured evidence
0%400 mg Q4W
NCT04163016 · Phase 1 · registry result, not featured evidence
0%200 mg Q2W
NCT04163016 · Phase 1 · registry result, not featured evidence
30.3%
NCT04740814 · Phase 1 · registry result, not featured evidence
Discontinued due to AEs
—Q2Wa
NCT03357471 · Phase 3 · Crohn's Disease, Psoriatic Arthritis, Rheumatoid Arthritis · phase 3
show 40 more results
—Q4W
NCT03357471 · Phase 3 · Crohn's Disease, Psoriatic Arthritis, Rheumatoid Arthritis · phase 3
16.1%
NCT00175877 · Phase 3
—
NCT02451748 · Phase 4 · registry result, not featured evidence · combination
—
NCT01500278 · Phase 4 · registry result, not featured evidence · combination
—
NCT01443364 · Phase 4 · registry result, not featured evidence
11.7%CDAI to Assess Response to Cimzia
NCT01255761 · Phase 4 · registry result, not featured evidence
7.9%RAPID3 to Assess Response to Cimzi
NCT01255761 · Phase 4 · registry result, not featured evidence
—
NCT01147341 · Phase 4 · registry result, not featured evidence
—400 mg
NCT00580840 · Phase 4 · registry result, not featured evidence · combination
—200 mg
NCT00580840 · Phase 4 · registry result, not featured evidence · combination
0.9%Cimzia
NCT00993668 · Phase 4 · registry result, not featured evidence
—Cimzia (Single Blind)
NCT00993668 · Phase 4 · registry result, not featured evidence
1.6%Open-label Cimzia (Cimzia in Feede
NCT02319642 · Phase 3 · registry result, not featured evidence
2.1%Open-label Cimzia (Placebo in Feed
NCT02319642 · Phase 3 · registry result, not featured evidence
—
NCT02151851 · Phase 3 · registry result, not featured evidence · combination
—
NCT01519791 · Phase 3 · registry result, not featured evidence · combination
—Q2W
NCT01521923 · Phase 3 · registry result, not featured evidence · combination
—Q4W
NCT01521923 · Phase 3 · registry result, not featured evidence · combination
5.6%
NCT01451203 · Phase 3 · registry result, not featured evidence · combination
14%400 mg
NCT00850343 · Phase 3 · registry result, not featured evidence
16.7%200 mg
NCT00850343 · Phase 3 · registry result, not featured evidence
14%200 mg
NCT00850343 · Phase 3 · registry result, not featured evidence
13.6%200 mg
NCT00850343 · Phase 3 · registry result, not featured evidence
10.7%
NCT01235598 · Phase 3 · registry result, not featured evidence
11.5%
NCT00843778 · Phase 3 · registry result, not featured evidence
—
NCT01374971 · Phase 3 · registry result, not featured evidence
18%
NCT00160641 · Phase 3 · registry result, not featured evidence
4.7%200mg
NCT00993317 · Phase 3 · registry result, not featured evidence · combination
2.4%
NCT00753454 · Phase 3 · registry result, not featured evidence
3.9%
NCT00717236 · Phase 3 · registry result, not featured evidence
24.1%
NCT00160693 · Phase 3 · registry result, not featured evidence
6.3%200 mg
NCT00674362 · Phase 3 · registry result, not featured evidence
6.9%200mg
NCT00791921 · Phase 3 · registry result, not featured evidence
8.2%400 mg
NCT00791999 · Phase 2/3 · registry result, not featured evidence
3.7%200 mg
NCT00791999 · Phase 2/3 · registry result, not featured evidence
4.2%100 mg
NCT00791999 · Phase 2/3 · registry result, not featured evidence
0%400 mg Q2W
NCT04163016 · Phase 1 · registry result, not featured evidence
0%400 mg Q4W
NCT04163016 · Phase 1 · registry result, not featured evidence
0%200 mg Q2W
NCT04163016 · Phase 1 · registry result, not featured evidence
9.1%
NCT04740814 · Phase 1 · registry result, not featured evidence
Serious AEs
0%Q2Wa
NCT03357471 · Phase 3 · Crohn's Disease, Psoriatic Arthritis, Rheumatoid Arthritis · phase 3
show 40 more results
0%Q4W
NCT03357471 · Phase 3 · Crohn's Disease, Psoriatic Arthritis, Rheumatoid Arthritis · phase 3
41.6%
NCT00175877 · Phase 3
0%
NCT02451748 · Phase 4 · registry result, not featured evidence · combination
13%
NCT01500278 · Phase 4 · registry result, not featured evidence · combination
12.1%
NCT01443364 · Phase 4 · registry result, not featured evidence
10.6%CDAI to Assess Response to Cimzia
NCT01255761 · Phase 4 · registry result, not featured evidence
8.7%RAPID3 to Assess Response to Cimzi
NCT01255761 · Phase 4 · registry result, not featured evidence
2.9%
NCT01147341 · Phase 4 · registry result, not featured evidence
2.9%400 mg
NCT00580840 · Phase 4 · registry result, not featured evidence · combination
7.1%200 mg
NCT00580840 · Phase 4 · registry result, not featured evidence · combination
—Cimzia
NCT00993668 · Phase 4 · registry result, not featured evidence
1.8%Cimzia (Single Blind)
NCT00993668 · Phase 4 · registry result, not featured evidence
2%Open-label Cimzia (Cimzia in Feede
NCT02319642 · Phase 3 · registry result, not featured evidence
6.3%Open-label Cimzia (Placebo in Feed
NCT02319642 · Phase 3 · registry result, not featured evidence
6.3%
NCT02151851 · Phase 3 · registry result, not featured evidence · combination
10.6%
NCT01519791 · Phase 3 · registry result, not featured evidence · combination
4.8%Q2W
NCT01521923 · Phase 3 · registry result, not featured evidence · combination
7.1%Q4W
NCT01521923 · Phase 3 · registry result, not featured evidence · combination
10.7%
NCT01451203 · Phase 3 · registry result, not featured evidence · combination
37.2%400 mg
NCT00850343 · Phase 3 · registry result, not featured evidence
25%200 mg
NCT00850343 · Phase 3 · registry result, not featured evidence
39.5%200 mg
NCT00850343 · Phase 3 · registry result, not featured evidence
36.4%200 mg
NCT00850343 · Phase 3 · registry result, not featured evidence
—
NCT01235598 · Phase 3 · registry result, not featured evidence
19.2%
NCT00843778 · Phase 3 · registry result, not featured evidence
0%
NCT01374971 · Phase 3 · registry result, not featured evidence
35.3%
NCT00160641 · Phase 3 · registry result, not featured evidence
9.4%200mg
NCT00993317 · Phase 3 · registry result, not featured evidence · combination
3%
NCT00753454 · Phase 3 · registry result, not featured evidence
6.1%
NCT00717236 · Phase 3 · registry result, not featured evidence
45.8%
NCT00160693 · Phase 3 · registry result, not featured evidence
5.2%200 mg
NCT00674362 · Phase 3 · registry result, not featured evidence
11.2%200mg
NCT00791921 · Phase 3 · registry result, not featured evidence
5.9%400 mg
NCT00791999 · Phase 2/3 · registry result, not featured evidence
4.9%200 mg
NCT00791999 · Phase 2/3 · registry result, not featured evidence
4.2%100 mg
NCT00791999 · Phase 2/3 · registry result, not featured evidence
—400 mg Q2W
NCT04163016 · Phase 1 · registry result, not featured evidence
20%400 mg Q4W
NCT04163016 · Phase 1 · registry result, not featured evidence
26.7%200 mg Q2W
NCT04163016 · Phase 1 · registry result, not featured evidence
6.1%
NCT04740814 · Phase 1 · registry result, not featured evidence
Most frequent reported AEs
a
hypertension 18.8%
nasopharyngitis 18.7%
urinary tract infection 17.7%
NCT00175877 · Phase 3
show 34 more results
nasopharyngitis 15.3%
headache 10.7%
upper respiratory tract infection 10.3%
NCT01500278 · Phase 4 · registry result, not featured evidence · combination
influenza 11.4%
arthralgia 6.8%
bronchitis 5.3%
NCT01443364 · Phase 4 · registry result, not featured evidence
upper respiratory tract infection 10.4%
urinary tract infection 10.4%
bronchitis 6%
NCT01255761 · Phase 4 · registry result, not featured evidence
urinary tract infection 10.6%
upper respiratory tract infection 10%
sinusitis 7.6%
NCT01255761 · Phase 4 · registry result, not featured evidence
upper respiratory infections 18.5% (placebo 0%)
rash 11.8% (placebo 0%)
bronchitis 8.8% (placebo 0%)
NCT01147341 · Phase 4 · registry result, not featured evidence
400 mg
upper respiratory tract infection 11.6% (placebo 14.5%)
urinary tract infection 8.7% (placebo 10.1%)
arthralgia 7.2% (placebo 2.9%)
NCT00580840 · Phase 4 · registry result, not featured evidence · combination
200 mg
upper respiratory tract infection 7.1% (placebo 14.5%)
urinary tract infection 7.1% (placebo 10.1%)
arthralgia 1.4% (placebo 2.9%)
NCT00580840 · Phase 4 · registry result, not featured evidence · combination
nasopharyngitis 9.1% (placebo 5.3%)
headache 7.3% (placebo 13.2%)
nausea 5.5% (placebo 5.3%)
NCT00993668 · Phase 4 · registry result, not featured evidence
upper respiratory tract infection 15.5%
anaemia 5.6%
liver function test abnormal 4.4%
NCT02319642 · Phase 3 · registry result, not featured evidence
upper respiratory tract infection 13.7%
anaemia 5.3%
liver function test abnormal 5.3%
NCT02319642 · Phase 3 · registry result, not featured evidence
upper respiratory tract infection 15.8% (placebo 13.3%)
latent tuberculosis 7.6% (placebo 6.2%)
liver function test abnormal 7% (placebo 3.5%)
NCT02151851 · Phase 3 · registry result, not featured evidence · combination
nausea 12.6% (placebo 10.1%)
upper respiratory tract infection 10.9% (placebo 5.1%)
urinary tract infection 7.3% (placebo 7.4%)
NCT01519791 · Phase 3 · registry result, not featured evidence · combination
Q2W
urinary tract infection 6% (placebo 2.5%)
nasopharyngitis 4.8% (placebo 6.2%)
hypercholesterolaemia 2.4% (placebo 3.7%)
NCT01521923 · Phase 3 · registry result, not featured evidence · combination
Q4W
nasopharyngitis 10.2% (placebo 6.2%)
hypercholesterolaemia 6.3% (placebo 3.7%)
latent tuberculosis 5.5% (placebo 0%)
NCT01521923 · Phase 3 · registry result, not featured evidence · combination
nasopharyngitis 44% (placebo 34.4%)
hepatic function abnormal 32.1% (placebo 30.6%)
nausea 24.5% (placebo 19.1%)
NCT01451203 · Phase 3 · registry result, not featured evidence · combination
400 mg
nasopharyngitis 44.2%
pharyngitis 16.3%
bronchitis 14%
NCT00850343 · Phase 3 · registry result, not featured evidence
200 mg
rheumatoid arthritis 25%
bronchitis 16.7%
constipation 16.7%
NCT00850343 · Phase 3 · registry result, not featured evidence
200 mg
nasopharyngitis 41.9%
eczema 27.9%
upper respiratory tract infection 20.9%
NCT00850343 · Phase 3 · registry result, not featured evidence
200 mg
nasopharyngitis 38.2%
eczema 18.2%
pharyngitis 15.5%
NCT00850343 · Phase 3 · registry result, not featured evidence
upper respiratory tract infection 9.2%
diarrhoea 6.2%
nasopharyngitis 6.2%
NCT00843778 · Phase 3 · registry result, not featured evidence
flare of rheumatoid arthritis 8.3%
headache 8.3%
injection site reaction 8.3%
NCT01374971 · Phase 3 · registry result, not featured evidence
upper respiratory tract infection 16%
hypertension 13.6%
rheumatoid arthritis 13.4%
NCT00160641 · Phase 3 · registry result, not featured evidence
200mg
upper respiratory tract infection 14.1% (placebo 11.9%)
nasopharyngitis 11.8% (placebo 9.5%)
abdominal pain upper 5.9% (placebo 4.8%)
NCT00993317 · Phase 3 · registry result, not featured evidence · combination
upper respiratory tract infection 13.7%
NCT00753454 · Phase 3 · registry result, not featured evidence
upper respiratory tract infection 7.3% (placebo 5.3%)
headache 5.4% (placebo 5.3%)
rheumatoid arthritis 4.4% (placebo 7.7%)
NCT00717236 · Phase 3 · registry result, not featured evidence
nasopharyngitis 35.1%
upper respiratory tract infection 23.1%
back pain 22.4%
NCT00160693 · Phase 3 · registry result, not featured evidence
200 mg
nasopharyngitis 10.4% (placebo 11.2%)
upper respiratory tract infection 6.3% (placebo 4.1%)
urinary tract infection 6.3% (placebo 5.1%)
NCT00674362 · Phase 3 · registry result, not featured evidence
200mg
nasopharyngitis 17.2% (placebo 14%)
rash 8.6% (placebo 0%)
eczema 5.2% (placebo 2.6%)
NCT00791921 · Phase 3 · registry result, not featured evidence
400 mg
nasopharyngitis 15.3% (placebo 11.7%)
hepatic function abnormal 5.9% (placebo 5.2%)
bronchitis 4.7% (placebo 1.3%)
NCT00791999 · Phase 2/3 · registry result, not featured evidence
200 mg
nasopharyngitis 13.4% (placebo 11.7%)
pharyngitis 6.1% (placebo 3.9%)
rash 4.9% (placebo 1.3%)
NCT00791999 · Phase 2/3 · registry result, not featured evidence
100 mg
hepatic function abnormal 11.1% (placebo 5.2%)
nasopharyngitis 11.1% (placebo 11.7%)
pharyngitis 6.9% (placebo 3.9%)
NCT00791999 · Phase 2/3 · registry result, not featured evidence
400 mg Q4W
influenza 40%
cystitis 20%
foetal vascular malperfusion 20%
NCT04163016 · Phase 1 · registry result, not featured evidence
200 mg Q2W
covid-19 40%
headache 20%
hypertension 13.3%
NCT04163016 · Phase 1 · registry result, not featured evidence
upper respiratory tract infection 9.1%
nausea 6.1%
rheumatoid arthritis 6.1%
NCT04740814 · Phase 1 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for 39 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

certolizumab pegol

ACR20 90.7% (n=43) @ 24wk400 mg
responder rate · % of participants
No placebo or comparator arm
NCT00850343 · Phase 3 · registry result, not featured evidence
show 26 more results
90.7% (n=43) @ 52wk400 mg
NCT00850343 · Phase 3 · registry result, not featured evidence
60.9% (n=110) @ 24wk200 mg
NCT00850343 · Phase 3 · registry result, not featured evidence
58.3% (n=12) @ 24wk200 mg
NCT00850343 · Phase 3 · registry result, not featured evidence
90.7% (n=43) @ 24wk200 mg
NCT00850343 · Phase 3 · registry result, not featured evidence
70% (n=110) @ 52wk200 mg
NCT00850343 · Phase 3 · registry result, not featured evidence
83.3% (n=12) @ 52wk200 mg
NCT00850343 · Phase 3 · registry result, not featured evidence
76.7% (n=43) @ 52wk200 mg
NCT00850343 · Phase 3 · registry result, not featured evidence
87% (n=733) @ 48wk
NCT00175877 · Phase 3
88% (n=668) @ 96wk
NCT00175877 · Phase 3
87.9% (n=602) @ 144wk
NCT00175877 · Phase 3
89.4% (n=537) @ 192wk
NCT00175877 · Phase 3
82.5% (n=183) @ 240wk
NCT00175877 · Phase 3
81.3% (n=841)
NCT00175877 · Phase 3
81.7% (n=493) @ 52wk
NCT00160641 · Phase 3 · registry result, not featured evidence
79.4% (n=442) @ 100wk
NCT00160641 · Phase 3 · registry result, not featured evidence
80.2% (n=410) @ 148wk
NCT00160641 · Phase 3 · registry result, not featured evidence
81.5% (n=367) @ 196wk
NCT00160641 · Phase 3 · registry result, not featured evidence
88.9% (n=72) @ 244wk
NCT00160641 · Phase 3 · registry result, not featured evidence
74.2% (n=565)
NCT00160641 · Phase 3 · registry result, not featured evidence
58.1% (n=370) @ 52wk
NCT00160693 · Phase 3 · registry result, not featured evidence
60% (n=275) @ 100wk
NCT00160693 · Phase 3 · registry result, not featured evidence
68.4% (n=247) @ 160wk
NCT00160693 · Phase 3 · registry result, not featured evidence
72.6% (n=223) @ 208wk
NCT00160693 · Phase 3 · registry result, not featured evidence
75.4% (n=211) @ 256wk
NCT00160693 · Phase 3 · registry result, not featured evidence
76.4% (n=140) @ 316wk
NCT00160693 · Phase 3 · registry result, not featured evidence
57.2% (n=402)
NCT00160693 · Phase 3 · registry result, not featured evidence
ACR50 74.4% (n=43) @ 24wk400 mg
responder rate · % of participants
No placebo or comparator arm
NCT00850343 · Phase 3 · registry result, not featured evidence
show 20 more results
69.8% (n=43) @ 52wk400 mg
NCT00850343 · Phase 3 · registry result, not featured evidence
29.1% (n=110) @ 24wk200 mg
NCT00850343 · Phase 3 · registry result, not featured evidence
41.7% (n=12) @ 24wk200 mg
NCT00850343 · Phase 3 · registry result, not featured evidence
69.8% (n=43) @ 24wk200 mg
NCT00850343 · Phase 3 · registry result, not featured evidence
40.9% (n=110) @ 52wk200 mg
NCT00850343 · Phase 3 · registry result, not featured evidence
58.3% (n=12) @ 52wk200 mg
NCT00850343 · Phase 3 · registry result, not featured evidence
62.8% (n=43) @ 52wk200 mg
NCT00850343 · Phase 3 · registry result, not featured evidence
63% (n=733) @ 48wk
NCT00175877 · Phase 3
66% (n=668) @ 96wk
NCT00175877 · Phase 3
65.4% (n=602) @ 144wk
NCT00175877 · Phase 3
64.8% (n=537) @ 192wk
NCT00175877 · Phase 3
58.5% (n=183) @ 240wk
NCT00175877 · Phase 3
57.6% (n=841)
NCT00175877 · Phase 3
48.9% (n=493) @ 52wk
NCT00160641 · Phase 3 · registry result, not featured evidence
51.4% (n=442) @ 100wk
NCT00160641 · Phase 3 · registry result, not featured evidence
51.7% (n=410) @ 148wk
NCT00160641 · Phase 3 · registry result, not featured evidence
56.9% (n=367) @ 196wk
NCT00160641 · Phase 3 · registry result, not featured evidence
62.5% (n=72) @ 244wk
NCT00160641 · Phase 3 · registry result, not featured evidence
47.4% (n=565)
NCT00160641 · Phase 3 · registry result, not featured evidence
27.6% (n=402)
NCT00160693 · Phase 3 · registry result, not featured evidence
ACR70 48.8% (n=43) @ 24wk400 mg
responder rate · % of participants
No placebo or comparator arm
NCT00850343 · Phase 3 · registry result, not featured evidence
show 20 more results
46.5% (n=43) @ 52wk400 mg
NCT00850343 · Phase 3 · registry result, not featured evidence
14.5% (n=110) @ 24wk200 mg
NCT00850343 · Phase 3 · registry result, not featured evidence
16.7% (n=12) @ 24wk200 mg
NCT00850343 · Phase 3 · registry result, not featured evidence
46.5% (n=43) @ 24wk200 mg
NCT00850343 · Phase 3 · registry result, not featured evidence
22.7% (n=110) @ 52wk200 mg
NCT00850343 · Phase 3 · registry result, not featured evidence
16.7% (n=12) @ 52wk200 mg
NCT00850343 · Phase 3 · registry result, not featured evidence
58.1% (n=43) @ 52wk200 mg
NCT00850343 · Phase 3 · registry result, not featured evidence
37.7% (n=733) @ 48wk
NCT00175877 · Phase 3
40.7% (n=668) @ 96wk
NCT00175877 · Phase 3
41.2% (n=602) @ 144wk
NCT00175877 · Phase 3
42.8% (n=537) @ 192wk
NCT00175877 · Phase 3
34.4% (n=183) @ 240wk
NCT00175877 · Phase 3
38.2% (n=841)
NCT00175877 · Phase 3
26.2% (n=493) @ 52wk
NCT00160641 · Phase 3 · registry result, not featured evidence
27.1% (n=442) @ 100wk
NCT00160641 · Phase 3 · registry result, not featured evidence
25.6% (n=410) @ 148wk
NCT00160641 · Phase 3 · registry result, not featured evidence
29.4% (n=367) @ 196wk
NCT00160641 · Phase 3 · registry result, not featured evidence
31.9% (n=72) @ 244wk
NCT00160641 · Phase 3 · registry result, not featured evidence
25.5% (n=565)
NCT00160641 · Phase 3 · registry result, not featured evidence
7.7% (n=402)
NCT00160693 · Phase 3 · registry result, not featured evidence
Modified Sharp -0.05 score @ 0wk400 mg
absolute change · score
No placebo or comparator arm
NCT00850343 · Phase 3 · registry result, not featured evidence
show 9 more results
1.85 score @ 100wk400 mg
NCT00850343 · Phase 3 · registry result, not featured evidence
1.48 score @ 0wk200 mg
NCT00850343 · Phase 3 · registry result, not featured evidence
2.18 score @ 0wk200 mg
NCT00850343 · Phase 3 · registry result, not featured evidence
0.77 score @ 0wk200 mg
NCT00850343 · Phase 3 · registry result, not featured evidence
7.89 score @ 100wk200 mg
NCT00850343 · Phase 3 · registry result, not featured evidence
8.73 score @ 100wk200 mg
NCT00850343 · Phase 3 · registry result, not featured evidence
2.07 score @ 100wk200 mg
NCT00850343 · Phase 3 · registry result, not featured evidence
0.95 score @ 96wk
NCT00175877 · Phase 3
0.99 score @ 104wk
NCT00160641 · Phase 3 · registry result, not featured evidence
HAQ-DI -0.674 score
absolute change · score
No placebo or comparator arm
NCT00175877 · Phase 3
show 2 more results
-0.567 score
NCT00160641 · Phase 3 · registry result, not featured evidence
-0.305 score
NCT00160693 · Phase 3 · registry result, not featured evidence
Morning Stiffness Duration -2.147 hours
absolute change · hours
No placebo or comparator arm
NCT00175877 · Phase 3
show 1 more result
-2.31 hours
NCT00160641 · Phase 3 · registry result, not featured evidence
DAS28-ESR -3.222 score
absolute change · score
No placebo or comparator arm
NCT00175877 · Phase 3
show 5 more results
-2.2 score @ 12wk
NCT01255761 · Phase 4 · registry result, not featured evidence
-2.11 score @ 12wk
NCT01255761 · Phase 4 · registry result, not featured evidence
-2.26 score @ 52wk
NCT01255761 · Phase 4 · registry result, not featured evidence
-2.14 score @ 52wk
NCT01255761 · Phase 4 · registry result, not featured evidence
-2.99 score
NCT00160641 · Phase 3 · registry result, not featured evidence
EULAR Good 42.4% (n=834)
responder rate · % of participants
No placebo or comparator arm
NCT00175877 · Phase 3
show 1 more result
36% (n=556)
NCT00160641 · Phase 3 · registry result, not featured evidence
SF-36 PCS 8.813 score
absolute change · score
No placebo or comparator arm
NCT00175877 · Phase 3
show 1 more result
6.628 score
NCT00160641 · Phase 3 · registry result, not featured evidence
SF-36 MCS 4.612 score
absolute change · score
No placebo or comparator arm
NCT00175877 · Phase 3
show 1 more result
4.325 score
NCT00160641 · Phase 3 · registry result, not featured evidence
ACR20 65.2% (n=69) vs 44.9% (n=69) placebo @ 34wk400 mg
responder rate · % of participants
NCT00580840 · Phase 4 · registry result, not featured evidence · combination
show 21 more results
77.6% (n=85) vs 28.6% (n=77) placebo @ 12wk400 mg
NCT00791999 · Phase 2/3 · registry result, not featured evidence
71.8% (n=85) vs 24.7% (n=77) placebo @ 24wk400 mg
NCT00791999 · Phase 2/3 · registry result, not featured evidence
67.1% (n=70) vs 44.9% (n=69) placebo @ 34wk200 mg
NCT00580840 · Phase 4 · registry result, not featured evidence · combination
36.5% (n=96) vs 15.3% (n=98) placebo @ 24wk200 mg
NCT00674362 · Phase 3 · registry result, not featured evidence
67.2% (n=116) vs 14.9% (n=114) placebo @ 12wk200mg
NCT00791921 · Phase 3 · registry result, not featured evidence
63.8% (n=116) vs 11.4% (n=114) placebo @ 24wk200mg
NCT00791921 · Phase 3 · registry result, not featured evidence
76.8% (n=82) vs 28.6% (n=77) placebo @ 12wk200 mg
NCT00791999 · Phase 2/3 · registry result, not featured evidence
73.2% (n=82) vs 24.7% (n=77) placebo @ 24wk200 mg
NCT00791999 · Phase 2/3 · registry result, not featured evidence
62.5% (n=72) vs 28.6% (n=77) placebo @ 12wk100 mg
NCT00791999 · Phase 2/3 · registry result, not featured evidence
61.1% (n=72) vs 24.7% (n=77) placebo @ 24wk100 mg
NCT00791999 · Phase 2/3 · registry result, not featured evidence
66.7% (n=81) vs 27.5% (n=40) placebo @ 24wk*200mg
NCT00993317 · Phase 3 · registry result, not featured evidence · combination · converted to % from 54 participants as posted
64.2% (n=81) vs 37.5% (n=40) placebo @ 12wk*200mg
NCT00993317 · Phase 3 · registry result, not featured evidence · combination · converted to % from 52 participants as posted
69.2% (n=454) vs 71.4% (n=454) ADA+MTX @ 12wk
NCT01500278 · Phase 4 · registry result, not featured evidence · combination
64.5% (n=454) vs 60.8% (n=454) ADA+MTX @ 6wk
NCT01500278 · Phase 4 · registry result, not featured evidence · combination
61.5% (n=26) vs 0% (n=9) placebo @ 12wk*
NCT01147341 · Phase 4 · registry result, not featured evidence · converted to % from 16 participants as posted
54.5% (n=22) vs 62.5% (n=8) placebo @ 24wk*
NCT01147341 · Phase 4 · registry result, not featured evidence · converted to % from 12 participants as posted
54.8% (n=312) vs 23.9% (n=113) placebo @ 24wk
NCT02151851 · Phase 3 · registry result, not featured evidence · combination
69% (n=655) vs 61.5% (n=213) placebo @ 52wk
NCT01519791 · Phase 3 · registry result, not featured evidence · combination
86.5% (n=126) vs 74.7% (n=79) placebo @ 104wkQ4W
NCT01521923 · Phase 3 · registry result, not featured evidence · combination
73.8% (n=84) vs 74.7% (n=79) placebo @ 104wkQ2W
NCT01521923 · Phase 3 · registry result, not featured evidence · combination
51.1% (n=851) vs 25.9% (n=212) placebo @ 12wk
NCT00717236 · Phase 3 · registry result, not featured evidence
DAS28-ESR LDAS 35.5% (n=454) vs 33.5% (n=454) ADA+MTX @ 104wk
responder rate · % of participants
NCT01500278 · Phase 4 · registry result, not featured evidence · combination
show 4 more results
45.6% (n=353) vs 42.4% (n=361) ADA+MTX @ 104wk
NCT01500278 · Phase 4 · registry result, not featured evidence · combination
20.5% (n=454) vs 18.1% (n=454) ADA+MTX @ 6wk
NCT01500278 · Phase 4 · registry result, not featured evidence · combination
30.4% (n=454) vs 29.7% (n=454) ADA+MTX @ 12wk
NCT01500278 · Phase 4 · registry result, not featured evidence · combination
47.7% (n=310) vs 46.6% (n=298) ADA+MTX @ 104wk
NCT01500278 · Phase 4 · registry result, not featured evidence · combination

+ 102 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: adalimumab-adbm (Cyltezo)'s landscape · certolizumab pegol's landscape